Disease by etiologic mechanism
MONDO:7770008A grouping class for human diseases classified by their etiologic mechanism, encompassing primarily intrinsic (genetic, genomic), primarily extrinsic (e.g., infections, toxins, radiation), and complex multifactorial (e.g. nutritional) causes.
60011 clinical trials for this condition and its sub-types, 0 tagged with Disease by etiologic mechanism itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Disease by etiologic mechanism
-
Cancer or benign tumor 0 trials · 33,026 incl. sub-types
5 sub-types
- Neoplastic disease or syndrome 7 trials · 32,694 incl. sub-types Sub-types →
- Precancerous condition 51 trials · 518 incl. sub-types Sub-types →
- Hyperplasia 5 trials · 272 incl. sub-types Sub-types →
- Polyp 14 trials · 200 incl. sub-types Sub-types →
- Cancer-related condition 16 trials · 36 incl. sub-types Sub-types →
-
Disease of genetic or genomic mechanism 2 trials · 18,336 incl. sub-types
2 sub-types
- Hereditary disease 193 trials · 18,193 incl. sub-types Sub-types →
- Chromosomal disorder 13 trials · 276 incl. sub-types Sub-types →
-
Disease of primarily extrinsic mechanism 0 trials · 10,582 incl. sub-types
7 sub-types
- Infectious disease 295 trials · 8,208 incl. sub-types Sub-types →
- Post-infectious disorder 2 trials · 1,771 incl. sub-types Sub-types →
- Disease related to transplantation 30 trials · 538 incl. sub-types Sub-types →
- Poisoning 69 trials · 311 incl. sub-types Sub-types →
- Occupational disorder 59 trials · 171 incl. sub-types Sub-types →
- Iatrogenic disease 19 trials · 136 incl. sub-types Sub-types →
- Radiation-induced disorder 7 trials · 93 incl. sub-types Sub-types →
-
Nutritional disorder 132 trials · 4,164 incl. sub-types
7 sub-types
- Overnutrition 15 trials · 3,249 incl. sub-types Sub-types →
- Nutritional deficiency disease 235 trials · 508 incl. sub-types Sub-types →
- Eating disorder 157 trials · 362 incl. sub-types Sub-types →
- Lactose intolerance 9 trials · 10 incl. sub-types Sub-types →
- Potassium deficiency disease 4 trials · 5 incl. sub-types Sub-types →
- Refeeding syndrome 4 trials
- Hemorrhagic disease of newborn 1 trial
-
Idiopathic disease 1 trial · 1,282 incl. sub-types
79 sub-types
- Fibromyalgia 279 trials
- Idiopathic interstitial pneumonia 10 trials · 219 incl. sub-types Sub-types →
- Idiopathic scoliosis 66 trials · 181 incl. sub-types Sub-types →
- Acquired idiopathic inflammatory myopathy 67 trials · 159 incl. sub-types Sub-types →
- Juvenile idiopathic arthritis 107 trials · 115 incl. sub-types Sub-types →
- Idiopathic urticaria 0 trials · 66 incl. sub-types Sub-types →
- Idiopathic membranous glomerulonephritis 50 trials
- Idiopathic hypersomnia 28 trials Sub-types →
- Idiopathic nephrotic syndrome 13 trials · 24 incl. sub-types Sub-types →
- Sudden unexpected death in pediatrics 1 trial · 17 incl. sub-types Sub-types →
- Cellular phase chronic idiopathic myelofibrosis 16 trials
- Idiopathic pulmonary arterial hypertension 15 trials
- Idiopathic spontaneous coronary artery dissection 15 trials
- Idiopathic bilateral vestibulopathy 14 trials
- Idiopathic achalasia 12 trials
- Pediatric acute-onset neuropsychiatric syndrome 8 trials · 10 incl. sub-types Sub-types →
- Idiopathic aplastic anemia 9 trials
- Persistent idiopathic facial pain 9 trials
- Idiopathic gastroparesis 8 trials
- Idiopathic recurrent pericarditis 8 trials
- Idiopathic CD4 lymphocytopenia 7 trials
- Idiopathic camptocormia 7 trials
- Myelodysplastic syndrome with ring sideroblasts 7 trials
- Idiopathic CD4-positive T-lymphocytopenia 6 trials
- Idiopathic torsion dystonia 6 trials Sub-types →
- Chronic idiopathic neuropathy 5 trials
- Idiopathic malabsorption due to bile acid synthesis defects 4 trials
- Idiopathic bronchiectasis 3 trials Sub-types →
- Idiopathic cardiomyopathy 2 trials · 3 incl. sub-types Sub-types →
- Idiopathic hypercalciuria 3 trials
- Idiopathic anaphylaxis 1 trial
- Idiopathic avascular necrosis 1 trial
- Idiopathic central precocious puberty 1 trial
- Idiopathic mast cell activation syndrome 1 trial
- Idiopathic posterior uveitis 1 trial
- Macular telangiectasia type 1 1 trial
- Nonimmune chronic idiopathic neutropenia of adults 1 trial
- Basal ganglia calcification, idiopathic, 1 0 trials
- Basal ganglia calcification, idiopathic, 4 0 trials
- Basal ganglia calcification, idiopathic, 5 0 trials
- Basal ganglia calcification, idiopathic, 6 0 trials
- Basal ganglia calcification, idiopathic, 7, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, 8, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, childhood-onset 0 trials
- Benign idiopathic neonatal seizures 0 trials
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 0 trials
- Diffuse idiopathic skeletal hyperostosis 0 trials
- Edema, familial idiopathic, prepubertal 0 trials
- Familial idiopathic dilatation of the right atrium 0 trials
- Idiopathic acute transverse myelitis 0 trials
- Idiopathic anterior uveitis 0 trials
- Idiopathic congenital hypothyroidism 0 trials
- Idiopathic copper-associated cirrhosis 0 trials
- Idiopathic corneal edema 0 trials
- Idiopathic disseminated cytomegalovirus infection 0 trials
- Idiopathic dropped head syndrome 0 trials
- Idiopathic ductopenia 0 trials
- Idiopathic eosinophilic pneumonia 0 trials Sub-types →
- Idiopathic granulomatous myositis 0 trials
- Idiopathic hemiconvulsion-hemiplegia syndrome 0 trials
- Idiopathic juvenile osteoporosis 0 trials
- Idiopathic linear interstitial keratitis 0 trials
- Idiopathic localized lipodystrophy 0 trials
- Idiopathic neonatal atrial flutter 0 trials
- Idiopathic panuveitis 0 trials Sub-types →
- Idiopathic peliosis hepatis 0 trials
- Idiopathic peripheral autonomic neuropathy 0 trials
- Idiopathic phalangeal acro-osteolysis 0 trials
- Idiopathic progressive polyneuropathy 0 trials
- Idiopathic pulmonary artery dilatation 0 trials
- Idiopathic recurrent stupor 0 trials
- Idiopathic severe pneumococcemia 0 trials
- Idiopathic syringomyelia 0 trials
- Intestinal pseudoobstruction, neuronal, chronic idiopathic, X-linked 0 trials
- Macular telangiectasia type 3 0 trials
- Polyhydramnios, chronic idiopathic 0 trials
- Priapism, familial idiopathic 0 trials
- Recurrent idiopathic neuroretinitis 0 trials
- Tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 12288 trials in this tab.
-
Rewriting the code: a One-Time gene fix for a rare immune disease?
Cure By invitation onlyThis trial tests a one-time gene therapy for WHIM syndrome, a rare inherited immune disorder that causes severe infections. Doctors collect a person's own blood stem cells, use base editing to correct the faulty CXCR4 gene, and return the edited cells to the body. The goal is to …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 21, 2026 13:00 UTC
-
Engineered immune cells target CS1 to fight stubborn myeloma
Cure OngoingResearchers are testing a new type of immune cell therapy called CS1-targeted CAR-T in adults with multiple myeloma that has come back or stopped responding to treatment. The study enrolls about 10 participants who have already received several lines of therapy. Doctors collect a…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Custom-Built immune cells take aim at a notorious cancer mutation
Cure OngoingResearchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can a One-Two radiation punch improve prostate cancer control?
Cure OngoingResearchers are testing a combination of two radiation techniques for men with intermediate or high risk prostate cancer. Participants receive a shortened course of external beam radiation followed by a single high-dose brachytherapy boost, with optional hormone therapy. The tria…
Phase 1/2 • Sponsor: German Oncology Center, Cyprus • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Targeted radiation aims to cure prostate cancer while sparing healthy tissue
Cure By invitation onlyResearchers in Denmark are testing a targeted radiation technique called focal brachytherapy for men with early prostate cancer. The treatment places radioactive sources directly into the tumor, guided by MRI and ultrasound, to destroy cancer while leaving the rest of the prostat…
Sponsor: Herlev Hospital • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Missing Iron-Carrying protein replaced in rare blood disorder
Cure OngoingAtransferrinemia is a rare inherited condition in which the body cannot make enough transferrin, a protein that moves iron through the blood. Without it, iron builds up in organs and red blood cells cannot form properly. Researchers are testing intravenous infusions of apotransfe…
Phase 2 • Sponsor: Prothya Biosolutions • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Could a Half-Matched donor cure a rare immune disease?
Cure OngoingThis early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…
Early phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can a Precision-Engineered transplant rebuild immunity in babies born without it?
Cure OngoingInfants with severe combined immunodeficiency (SCID) lack working immune cells and face life-threatening infections. A matched sibling donor transplant is the standard cure, but most babies do not have one. This trial tests a refined transplant using a parent or other partially m…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
New flu vaccine candidate enters human testing
Vaccine CancelledThis early-stage trial compares an experimental flu vaccine called H1ssF with the standard seasonal flu vaccine (Flucelvax). About 112 adults aged 18-70 will take part, including some who have had flu shots before and some who have never had one. The main goal is to check safety …
Phase 1 • Sponsor: University of Minnesota • Aim: Vaccine
Last updated Sep 21, 2026 13:00 UTC
-
New west nile vaccine enters first human tests
Vaccine OngoingThis early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will comp…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
New vaccine aimed at training immune system to fight advanced breast cancer enters first human tests
Vaccine OngoingThis early-stage trial tests a new vaccine called ES2B-C001, with or without an immune booster (adjuvant), in 40 people with HER2-positive metastatic breast cancer who have already tried other treatments. The vaccine is designed to help the body's immune system recognize and atta…
Phase 1 • Sponsor: ExpreS2ion Biotechnologies • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
Massive malawi trial aims to shield kids from typhoid
Vaccine OngoingThis large phase 3 trial is testing a typhoid conjugate vaccine (Vi-TCV) in 30,000 healthy children aged 9 months to 12 years in Malawi. Half get the typhoid vaccine, half get a meningitis vaccine for comparison. The goal is to see if the typhoid vaccine prevents blood-confirmed …
Phase 3 • Sponsor: University of Maryland, Baltimore • Aim: Vaccine
Last updated Sep 19, 2026 00:00 UTC
-
New maintenance treatment aims to keep favorable risk AML in remission
Disease control OngoingThis study tests whether a maintenance therapy using a hypomethylating agent (HMA) can help prevent relapse and improve survival in people with favorable risk acute myeloid leukemia (AML). About 77 participants who are already in remission after initial treatment will receive HMA…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
Protein-Packed breast milk could help tiny preemies grow stronger
Disease control OngoingThis study tests whether adding extra protein to breast milk during the first two weeks of life helps extremely preterm infants (born at 28 weeks or earlier) gain more lean body mass and develop a healthier gut microbiome. About 150 babies will be randomly assigned to receive eit…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New spinal fluid treatment targets deadly cancer spread
Disease control OngoingThis study tests a new treatment for leptomeningeal metastasis, a condition where cancer spreads to the lining of the brain and spinal cord. The treatment combines an immune checkpoint inhibitor (a drug that helps the immune system fight cancer) with pemetrexed (a chemotherapy dr…
Phase 1/2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control OngoingThis phase 3 trial tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) whose cancer has stopped responding to the drug osimertinib. Abo…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
Stick to a schedule to beat Pre-Diabetes?
Disease control OngoingThis study tests whether keeping a consistent daily routine—like eating and sleeping at the same times—can improve blood sugar control and reduce body fat in people with pre-diabetes. Researchers will enroll 34 adults and ask half to follow a fixed schedule for 12 weeks. The goal…
Sponsor: Columbia University • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control By invitation onlyThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New vaccine plus immunotherapy shows promise against HPV-Linked head and neck cancer
Disease control OngoingThis trial tests whether adding a vaccine called BNT113 to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer linked to HPV16. About 350 participants will receive either the combination or the standard single d…
Phase 2/3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New drug SAT-3247 tested for long-term muscle protection in duchenne MD
Disease control By invitation onlyThis study looks at the long-term safety and effects of a drug called SAT-3247 in 10 people with Duchenne muscular dystrophy who were in a previous trial. Participants take the drug by mouth five days a week for about 11 months. Researchers will check for side effects and measure…
Phase 2 • Sponsor: Satellos Bioscience, Inc. • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New pill combo shows promise for tough thyroid cancer
Disease control OngoingThis phase 3 study tests whether two targeted cancer pills, dabrafenib and trametinib, can help people with advanced thyroid cancer that has a specific gene change (BRAF V600E) and no longer responds to radioactive iodine. About 153 adults who have already tried one or two other …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New vaccine combo shows promise in ovarian cancer fight
Disease control OngoingThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
Can antibodies flush out hidden HIV? new trial aims to find out
Disease control OngoingThis study tests whether two lab-made antibodies, 3BNC117-LS and 10-1074-LS, can safely reduce the hidden HIV reservoir in people already on suppressive antiretroviral therapy (ART). The trial involves 105 adults with HIV who will receive three infusions of the antibodies or a pl…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
Promising combo aims to stall advanced prostate cancer
Disease control OngoingThis phase 3 trial tests whether adding the drug niraparib to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 765 men with specific genetic changes are taking part. The study compa…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New drug cocktail shows promise for tough lung cancer
Disease control OngoingThis study tests a combination of drugs (berzosertib, carboplatin, gemcitabine, and pembrolizumab) in people with advanced squamous non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo helps control the cancer longer than standard tre…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Could TB treatment be cut from 6 months to 17 weeks?
Disease control OngoingThis study tests whether two new 17-week drug combinations can treat pulmonary tuberculosis as effectively as the standard 6-month regimen. About 288 people with TB will receive one of three daily pill regimens. The goal is to see if shorter treatment can clear the infection fast…
Phase 2/3 • Sponsor: Centers for Disease Control and Prevention • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Could lung cancer patients get immunotherapy less often?
Disease control OngoingThis study tests whether giving the immunotherapy drug pembrolizumab every 12 weeks works as well as the standard every 3 weeks in people with non-small cell lung cancer who are already benefiting from the drug. The goal is to see if fewer treatments can keep the cancer under con…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New targeted pill shows promise for tough bladder cancers
Disease control OngoingThis study tests a targeted pill (erdafitinib) against standard chemotherapy or immunotherapy in people with advanced bladder cancer that has specific FGFR gene changes. About 629 participants whose cancer worsened after prior treatments will be randomly assigned to receive erdaf…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Vacuum therapy may stop deadly leaks after esophageal cancer surgery
Disease control OngoingThis study tests a special vacuum device placed inside the esophagus right after cancer surgery to prevent dangerous leaks where the stomach is reconnected to the esophagus. About 44 adults having minimally invasive esophageal cancer surgery will receive this preventive treatment…
Sponsor: Aesculap AG • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat throat cancer
Disease control PausedThis study tests whether adding the targeted therapy cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) can better control advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy an…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New lung cancer combo aims to outperform current standard in consolidation therapy
Disease control OngoingThis study tests whether a new drug combination (BMS-986489) works better than the current standard (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults whose cancer hasn't spread widely will be randomly assigned to o…
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New combo therapy targets untreatable liver cancer
Disease control OngoingThis phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Supercharged immune cells aim to beat back tough leukemia
Disease control OngoingThis phase 2 trial tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) a special type of immune cell—called a cytokine-induced memory-like natural killer (NK) cell—after a stem cell transplant can improve their chances of staying cancer-free. About 60 ad…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug combo shows promise for rare kidney cancer
Disease control OngoingThis trial tests a combination of two drugs—anlotinib (a pill that blocks blood vessel growth to tumors) and sintilimab (an IV immunotherapy that helps the immune system attack cancer cells)—as a first treatment for people with advanced non-clear cell renal cell carcinoma, a rare…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug aims to tame muscle inflammation in myositis
Disease control OngoingThis phase 2 trial tests whether nipocalimab, given intravenously, can improve symptoms of active idiopathic inflammatory myopathies (myositis) better than a placebo. About 36 adults with myositis will receive either nipocalimab or a placebo, along with standard steroid treatment…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Which heat treatment shrinks thyroid nodules better?
Disease control OngoingThis trial compares two minimally invasive procedures, radiofrequency ablation (RFA) and microwave ablation (MWA), for treating large benign thyroid nodules. Adults with a single nodule of at least 20 milliliters will be randomly assigned to one of the two heat-based treatments. …
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Inhaled drug combo aims to boost lung cancer treatment before surgery
Disease control PausedThis study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug obrixtamig targets Hard-to-Treat lung and neuroendocrine cancers in first human trial
Disease control OngoingThis early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Weight-Loss drug added to arthritis therapy shows promise in new trial
Disease control OngoingThis study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New tool helps doctors and patients tackle obesity in diabetes
Disease control OngoingThis study tests a web-based tool called the BMI-CDS (Weight Loss Wizard) in 40 primary care clinics. The tool gives doctors and patients with type 2 diabetes and obesity personalized estimates of the benefits and risks of treatments like weight-loss surgery or medication. Over 1…
Sponsor: HealthPartners Institute • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Lung cancer trial asks: is it better to start with immunotherapy alone?
Disease control OngoingThis phase III trial is testing two different treatment sequences for people with advanced non-squamous non-small cell lung cancer. One group starts with the immunotherapy drug pembrolizumab alone, then adds chemotherapy only if the cancer progresses. The other group receives pem…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Malaria drug may boost melanoma immunotherapy
Disease control OngoingThis study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) can help shrink advanced melanoma tumors. About 41 adults with stage III or IV melanoma that cannot be removed by surgery are participating. The go…
Phase 1/2 • Sponsor: Ravi Amaravadi, MD • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New combo therapy aims to stall pancreatic cancer in BRCA patients
Disease control OngoingThis phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for controlling metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Can an immunotherapy combo shrink stomach tumors before surgery?
Disease control OngoingThis trial tests whether adding the immunotherapy drug toripalimab to two different chemotherapy regimens, given before surgery, can help people with locally advanced gastric adenocarcinoma. About 248 adults with HER2-negative stomach cancer will receive either docetaxel, oxalipl…
Phase 2/3 • Sponsor: Peking University • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Targeted radiation zaps glioblastoma cells after surgery
Disease control OngoingThis early-phase trial tests a new treatment for glioblastoma, an aggressive brain cancer. After standard therapy (surgery, chemo, radiation), a radioactive antibody is injected into the brain cavity to target remaining tumor cells and delay recurrence. The study enrolls 15 adult…
Phase 1 • Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Could keytruda tame tough prostate cancers?
Disease control OngoingThis phase 2 study tests pembrolizumab (Keytruda) in 40 men with metastatic castration-resistant prostate cancer that has specific genetic flaws (mismatch repair deficiency or CDK12 inactivation). The goal is to see if the drug can shrink tumors or slow the cancer. Researchers wi…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New pill could tame tough psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 774 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is to measure imp…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New combo shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New combo shows promise for tough kidney cancers
Disease control OngoingThis study tests two drugs, nivolumab and cabozantinib, together in 60 people with advanced or metastatic non-clear cell kidney cancer. The goal is to see how well the combination shrinks tumors. Participants take cabozantinib daily and receive nivolumab infusions every two weeks…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Surgery plus drug: a new combo for obesity?
Disease control OngoingThis early study looks at whether taking tirzepatide (Mounjaro) after sleeve gastrectomy surgery helps people lose more weight and improve conditions like diabetes and high blood pressure. About 42 adults with obesity will be split into two groups: one gets surgery alone, the oth…
Early phase 1 • Sponsor: Nicholas Skertich • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Can a targeted drug hit the mark against HER2-mutated lung cancer?
Disease control OngoingThis trial is testing an experimental drug called BL-M07D1 in people with a specific type of advanced non-small cell lung cancer that has a HER2 mutation. The study aims to find the best dose and see how well the drug shrinks tumors, while also checking for side effects. Particip…
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Experimental vaccine aims to stop lung cancer from coming back
Disease control PausedThis trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New hope for kids with tough brain tumors: targeted drug shows promise
Disease control OngoingThis study tests a drug called selumetinib in children and young adults with low grade glioma that has come back or not responded to other treatments. The drug works by blocking certain enzymes that help tumor cells grow. The goal is to find the best dose and see if it can shrink…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Could a common diabetes drug help manage cystic Fibrosis-Related diabetes?
Disease control OngoingThis pilot study tests the safety and feasibility of empagliflozin (Jardiance) in 8 overweight or obese adults with cystic fibrosis-related diabetes (CFRD) who are already on insulin. Participants will receive either the drug or a placebo in a crossover design. The goal is to gat…
Phase 2/3 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New combo aims to stop lung Cancer's return after surgery
Disease control OngoingThis study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New antibody drug conjugate tested against advanced cancers
Disease control OngoingResearchers are running a first-in-human phase 1 study of TORL-4-500, an antibody drug conjugate, in adults with advanced solid tumors, including hepatocellular carcinoma. The study has two parts: one to find the highest safe dose and the recommended dose for later trials, and an…
Phase 1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New pill targets genetic form of polycystic kidney disease
Disease control OngoingThis study tests an experimental drug called VX-407 in 24 adults with autosomal dominant polycystic kidney disease (ADPKD) who have specific changes in the PKD1 gene. The goal is to see if the drug can slow kidney growth and is safe. Participants take VX-407 tablets by mouth and …
Phase 2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Immunotherapy drug blinatumomab aims to boost leukemia survival in major trial
Disease control OngoingThis Phase III trial is testing whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a newly diagnosed type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 participants are randomly assigned to rece…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug cocktail targets Hard-to-Treat myeloma
Disease control PausedThis study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Brain cancer vaccine trial combines custom peptides with electric fields
Disease control OngoingThis early-phase trial tests whether a personalized vaccine made from each patient's tumor mutations, combined with Tumor Treating Fields (a device that sends electric fields to the brain), is safe and feasible for people with newly diagnosed glioblastoma. The 13 participants rec…
Phase 1 • Sponsor: Adilia Hormigo • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New hope for post-transplant bladder bleeding: cidofovir shows promise
Disease control OngoingThis study looked at whether adding the drug cidofovir to usual care helps people who develop painful bladder bleeding from the BK virus after a stem cell transplant. About 27 participants received either cidofovir or standard supportive care. The goal was to see if symptoms impr…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug could ease sleep apnea and help shed pounds
Disease control OngoingThis study tests a new medicine, maridebart cafraglutide, for adults with obstructive sleep apnea who are overweight or obese and already use a CPAP machine. The goal is to see if the drug can reduce breathing pauses during sleep and help with weight loss over 52 weeks. About 250…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail of drugs aimed at halting bone metastases in prostate cancer
Disease control PausedThis study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Breast cancer drug ribociclib made available Long-Term in new study
Disease control OngoingThis study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while re…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aims to stop brain bleeds in rare disease
Disease control OngoingThis study tests an experimental drug called ALN-APP in 200 adults with cerebral amyloid angiopathy (CAA), a condition that causes bleeding in the brain. The drug is given via spinal injection and aims to slow disease progression and reduce new brain bleeds. Participants will be …
Phase 2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Real-World lupus drug study launches in poland
Disease control OngoingThis study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of contr…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New mRNA vaccine combo aims to stop lung cancer recurrence
Disease control OngoingThis Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a single dose of radiation during surgery improve pancreatic cancer outcomes?
Disease control OngoingThis trial is testing whether giving a single dose of radiation directly to the tumor area during surgery is safe for people with localized pancreatic cancer. Participants first receive standard chemotherapy and stereotactic body radiation therapy (SBRT), then at the time of surg…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Hope for early breast cancer: targeted drug may cut recurrence risk
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental drug ION717 aims to slow fatal brain disease
Disease control OngoingThis study tests a new drug called ION717 for people with early-stage prion disease, a rare and fatal brain condition. The drug is given via a spinal injection and aims to reduce harmful prion proteins. The trial will check safety, side effects, and how the drug moves through the…
Phase 1/2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo targets genetic weakness in advanced breast cancer
Disease control OngoingThis study tests a combination of two drugs—alpelisib (a targeted therapy) and fulvestrant (a hormone blocker)—in Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA mutation. The cancer must have worsened after prior…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New Three-Drug cocktail aims to tackle tough lymphomas
Disease control OngoingThis study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail takes on glioblastoma in early trial
Disease control OngoingThis early-stage study tests whether adding an experimental drug called OKN-007 to standard chemoradiotherapy is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 participants will receive the combination after surgery. The mai…
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can special glasses stop Kids' eyesight from getting worse?
Disease control OngoingThis study tests whether new spectacle lenses can safely slow the progression of myopia (nearsightedness) in children. About 249 kids will wear either the novel lenses or standard single vision glasses for 36 months. Researchers will measure changes in eye length and prescription…
Sponsor: HOYA Lens Thailand LTD. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New triple therapy aims to halt advanced breast cancer
Disease control OngoingThis study tests a combination of two experimental drugs (LEE011 and BYL719) plus a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the triple combination can better control the cancer. Participant…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug JSB462 tested for advanced prostate cancer in japanese patients
Disease control OngoingThis early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat carcinoid tumors
Disease control OngoingThis Phase II trial tests whether combining lenvatinib and everolimus can shrink or slow advanced carcinoid tumors that cannot be removed by surgery. The study enrolls 36 adults with confirmed unresectable carcinoid tumors. Both drugs are taken orally and work by blocking enzymes…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat lung cancer
Disease control PausedThis early-phase trial is testing whether combining two drugs—vismodegib and atezolizumab—is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer cells grow, while atezolizumab helps…
Phase 1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat gut tumors
Disease control OngoingThis early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aims to slow kidney failure in rare genetic disease
Disease control OngoingThis study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that damages kidneys, hearing, and eyes. The drug works by blocking a protein thought to cause kidney injury, with the goal of slowing the loss of ki…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive Bone-Seeking drug paired with chemo shows promise for advanced breast cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for seniors with aggressive blood cancer: targeted combo shows promise
Disease control OngoingThis study tests whether adding a targeted drug called polatuzumab vedotin to a standard chemotherapy regimen (R-miniCHP) can help people aged 75 and older with a type of lymphoma called DLBCL. The goal is to see if the combination improves how long patients live without their ca…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New study aims to boost growth and health in kids with thalassemia
Disease control OngoingThis study looks at growth problems in children with thalassemia, a blood disorder. Researchers will test a program that includes health education, nutrition plans, exercise, and support to help kids grow better. The goal is to improve height, weight, and overall well-being in 36…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Brain pacemaker tested for Musician's hand cramps
Disease control OngoingThis study tests deep brain stimulation (DBS) surgery for people with severe focal hand dystonia, including musician's dystonia, that hasn't improved with botulinum toxin. Five participants will have electrodes placed in brain areas that control movement, connected to a stimulato…
Phase 1/2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immunotherapy combo shows promise in preventing High-Risk uterine cancer return
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can adding surgery or radiation to immunotherapy boost survival in advanced lung cancer?
Disease control OngoingThis study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
One patient keeps receiving experimental colorectal cancer drug pair
Disease control Expanded access (ended)This expanded access program provides continued treatment with CA102N plus lonsurf to a single patient with advanced or metastatic colorectal cancer. The patient had already completed at least 12 cycles of the same combination in an earlier clinical study. Expanded access allows …
Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could vitamin c boost liver transplant success?
Disease control CancelledThis study tests whether high doses of vitamin C given through an IV can help people recover better after a liver transplant. About 90 adults having their first liver transplant will receive either vitamin C or a placebo for two days. The goal is to see if vitamin C reduces organ…
Phase 4 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Phase 1 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Higher-Dose eye injection shows promise for two leading causes of vision loss
Disease control OngoingThis study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks to people with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME). The goal is to see if this dosing schedule is safe and works well for those who have a…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New daily shot could help kids with hemophilia avoid bleeds
Disease control OngoingThis study tests a daily injection called concizumab in children under 12 with hemophilia A or B, with or without inhibitors. The goal is to see if it safely prevents bleeding episodes. Participants receive daily shots under the skin for at least 2 years, and the study tracks how…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a hyaluronic acid drug combo outperform bevacizumab in Hard-to-Treat colon cancer?
Disease control PausedResearchers are testing whether adding an experimental drug called CA102N to the chemotherapy TAS-102 helps control metastatic colorectal cancer better than adding bevacizumab to TAS-102. The trial enrolls about 100 adults whose cancer has grown after standard chemotherapy. Parti…
Phase 2 • Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted drug shows promise for rare ROS1 cancers
Disease control OngoingThis study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a simpler scope technique match the complex one for large colon growths?
Disease control OngoingResearchers compare two ways to remove large, non-cancerous growths from the colon. One method, endoscopic mucosal resection, removes the growth in pieces. The other, endoscopic submucosal dissection, removes it in one piece but takes longer and carries more risk. The trial tests…
Sponsor: José Carlos Marín Gabriel • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted pill combo in final testing
Disease control OngoingThis phase 3 study tests whether adding alpelisib (a targeted pill) to fulvestrant (a hormone-blocking shot) can slow cancer growth in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. Participants must have already tr…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an AI eye guide surgeons to safer, faster cancer removal?
Disease control OngoingThis trial tests an artificial intelligence system called ADTPS that helps doctors remove early-stage esophageal cancer or precancerous lesions using a scope. The AI analyzes live images during the procedure and overlays a suggested cutting path on the screen. Half of the partici…
Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Double-Target immunotherapy added to standard care for aggressive cervical cancer
Disease control By invitation onlyResearchers are testing whether adding cadonilimab, an immunotherapy drug, to chemotherapy before and after standard chemoradiation can help women with high-risk, locally advanced cervical cancer. The trial enrolls 20 women who have not received prior treatment. Participants rece…
Sponsor: Hubei Cancer Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug shows promise for Crohn's sufferers in Mid-Stage trial
Disease control OngoingThis study tests a new drug called AZD7798 in 120 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and improve the appearance of the gut lining. Participants are randomly assigned to receive either the drug or a placebo, and neither the…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New psoriasis drug shows promise for kids in Head-to-Head trial
Disease control OngoingThis study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can Device-Preserved donor lungs boost transplant success?
Disease control By invitation onlyThis registry collects data on lung transplant patients whose donor lungs were preserved and transported using the LUNGguard or BAROguard devices. Researchers track outcomes such as primary graft dysfunction, rejection, survival, ICU and hospital stays, readmissions, and time on …
Sponsor: Paragonix Technologies • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in large trial
Disease control By invitation onlyThis study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis study tests a new drug, seclidemstat, combined with a standard drug, azacitidine, for people with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to find the best dose and see if the combination can shrink or control the cancer. About 2…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to deepen remission in early CML
Disease control OngoingThis study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combin…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to stall breast cancer in patients with key gene mutation
Disease control OngoingThis phase II study tests whether adding alpelisib (a targeted pill) to standard fulvestrant (a hormone-blocking shot) can delay cancer growth in Chinese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that has wors…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can adding surgery or radiation to a targeted pill slow lung cancer better?
Disease control OngoingThis study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to slow prostate cancer spread
Disease control OngoingThis study tests a new drug, JSB462, combined with standard therapy (abiraterone) in 150 men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination lowers PSA levels more effectively and delays cancer growth. Participants w…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immunotherapy duo takes on resistant germ cell tumors
Disease control OngoingThis phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail of drugs and radiation aims to boost stomach cancer treatment before surgery
Disease control OngoingThis pilot study tests whether giving a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation therapy before surgery can help treat stomach cancer that can be surgically removed. The study includes 32 participants and primarily lo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Freezing tumors to boost cancer treatment: early trial underway
Disease control OngoingThis early-phase trial tests a freezing treatment called cryotherapy, given before and during standard chemoradiation, for people with locally advanced esophageal cancer. The main goal is to find the safest number of cryotherapy sessions. Researchers will also check if the freezi…
Phase 1 • Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immune cells take on tough tumors in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…
Phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill combo aims to keep advanced breast cancer in check
Disease control OngoingThis Phase 3 study tests whether adding the targeted drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can help people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation) live longer without their cancer growing…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New gene therapy targets Parkinson's in patients with specific gene flaw
Disease control OngoingThis study tests a new gene therapy called LY3884961 in 32 people with moderate to severe Parkinson's disease who have a specific genetic change (GBA1 mutation). The treatment is given as a single injection into the fluid around the brain and spinal cord. The main goal is to chec…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to tackle melanoma that resists treatment
Disease control OngoingThis phase 2 trial is testing whether a combination of two drugs, enfortumab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma that has worsened after standard therapy. The study will enroll 60 adults with unresectable stage III or IV melanoma. Researc…
Phase 2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingThis Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Double antibiotic attack on staph blood infections shows promise
Disease control By invitation onlyThis study tests whether giving two IV antibiotics early, instead of one, can clear Staphylococcus aureus bloodstream infections faster and improve outcomes. About 300 hospitalized adults will be randomly assigned to receive either a single antibiotic or a combination of two. Onc…
Phase 4 • Sponsor: West Virginia University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a shorter radiation zap before surgery be just as good for sarcoma patients?
Disease control OngoingThis study compares the usual 5-week radiation schedule before sarcoma surgery to a shorter 2-week course. Researchers want to see if the shorter course leads to similar wound healing and tumor control. About 168 adults with soft tissue sarcomas in the head, neck, trunk, or limbs…
Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma
Disease control OngoingThis early-phase study tests a new treatment for multiple myeloma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carrying a protein called CD138. …
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for chinese patients with severe transplant complication: ruxolitinib trial launches
Disease control OngoingThis study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patie…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase 2/3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy shows promise for Radioiodine-Resistant thyroid cancer
Disease control OngoingThis phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New radiation approach may offer shorter, safer treatment for recurrent prostate cancer
Disease control OngoingThis study tests whether a precise, short-course radiation method (SBRT) works as well as a slightly longer radiation approach (hypofractionated radiotherapy) for men whose prostate cancer has come back or spread to a few spots after surgery. About 118 participants will receive o…
Phase 3 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cocktail of drugs tested for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for kids with pompe: enzyme combo trial underway
Disease control OngoingThis study tests a new treatment called cipaglucosidase alfa/miglustat in children (0 to under 18 years) with late-onset Pompe disease. The goal is to see if it is safe and how well it works. Participants either have never had enzyme therapy before or have been on it for at least…
Phase 3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug iberdomide takes on lenalidomide in battle to keep myeloma at bay
Disease control OngoingThis phase 3 trial tests whether iberdomide is better than lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer progression longer. The st…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to wipe out lingering leukemia before transplant
Disease control OngoingThis phase 2 trial tests whether a combination of venetoclax and azacitidine can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who still have or develop leftover cancer cells after initial chemotherapy, and before a stem cell transplant. Abou…
Phase 2 • Sponsor: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug combo enters human testing
Disease control OngoingThis early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Two biologics go head to head in ulcerative colitis
Disease control OngoingResearchers compare two biologic drugs, ustekinumab and infliximab, in adults with moderate to severe ulcerative colitis who have not previously tried biologic therapy. The trial measures how well each drug reduces inflammation, controls symptoms, and improves quality of life, wh…
Sponsor: Helwan University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a Platelet-Boosting drug help control a rare bone marrow disorder?
Disease control OngoingResearchers are observing how well eltrombopag works in adults with hypocellular myelodysplastic neoplasms, a bone marrow condition that lowers blood cell counts. The study follows patients in Italy who receive eltrombopag alone or with immunosuppressive therapy as part of routin…
Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill hopes to boost blood in bone marrow disease
Disease control OngoingThis study tests an experimental drug, HT-6184, in adults with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). The goal is to see if the drug can improve blood counts and reduce the need for transfusions. Participants take…
Phase 2 • Sponsor: Halia Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Custom RNA vaccine aims to supercharge cancer immunotherapy
Disease control PausedThis early-phase trial tests a personalized RNA nanoparticle vaccine made from a patient's own tumor. The goal is to help anti-PD-1 immunotherapy work better in people with advanced melanoma or soft tissue sarcoma whose cancer has progressed on standard treatment. Up to 18 partic…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a targeted drug outperform chemotherapy in Tough-to-Treat nasopharyngeal cancer?
Disease control OngoingThis phase III trial compares an experimental drug called YL201 with standard chemotherapy in people whose nasopharyngeal carcinoma has returned or spread and no longer responds to PD-(L)1 inhibitors and at least two prior chemotherapy regimens. About 400 participants will receiv…
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New study tests everolimus for kidney tumors in TSC patients
Disease control OngoingThis study looks at how safe and effective the drug everolimus is for Taiwanese adults with tuberous sclerosis complex (TSC) who have kidney tumors called angiomyolipomas. Four participants will take the drug and be monitored for side effects and tumor shrinkage. The goal is to c…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Robot-Assisted colonoscopy: a safer scope?
Disease control OngoingThis study will test a new robotic device called the Triton 1.5 System for performing colonoscopies, which are exams to look for colon cancer. About 40 adults who need a routine colonoscopy will take part. The main goal is to see if the robot is safe and can successfully complete…
Sponsor: Neptune Medical • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New oil therapy could slash Life-Threatening events in kids with rare metabolic disease
Disease control OngoingThis study tests whether triheptanoin, a special oil, can reduce major clinical events (like severe low blood sugar or heart problems) in children with long-chain fatty acid oxidation disorders (LC-FAOD), a rare condition where the body can't break down certain fats for energy. A…
Phase 3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Lifeline for ALK cancer patients: continued access to ceritinib
Disease control OngoingThis study offers continued treatment with the drug ceritinib to people with ALK-positive cancers who were already benefiting from it in a previous Novartis study. The main goal is to track safety and side effects over time. About 233 participants will receive the drug as long as…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New shot shrinks skin cancer before surgery in early trial
Disease control OngoingThis study tests an experimental drug called BO-112, injected directly into basal cell skin cancer tumors before they are surgically removed. The goal is to see if the drug is safe and helps shrink or eliminate the cancer. About 60 adults with low- or high-risk basal cell carcino…
Phase 2 • Sponsor: Highlight Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase 1/2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy aims to keep multiple myeloma in check longer
Disease control OngoingThis phase 3 study tests whether adding daratumumab to the standard drug lenalidomide as maintenance therapy after a stem cell transplant can better control multiple myeloma. About 1,100 participants will be randomly assigned to receive either lenalidomide alone or lenalidomide p…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Shorter, stronger radiation beams tested for prostate cancer
Disease control OngoingThis study tests whether a shorter, more intense radiation treatment (5 sessions) is better than the standard 20-session approach for men with intermediate- or high-risk prostate cancer that hasn't spread. The goal is to improve cancer control while keeping side effects low. Abou…
Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Device aims to keep donor livers healthier for transplant
Disease control By invitation onlyResearchers are collecting data on how well donor livers preserved with the LIVERguard device function after transplantation. The study includes liver transplant recipients whose donor organs were stored in the device, as well as a comparison group of patients who received livers…
Sponsor: Paragonix Technologies • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Hope for becker MD: new drug shows promise in Long-Term trial
Disease control By invitation onlyThis study looks at the long-term safety and effects of a drug called EDG-5506 (sevasemten) in people with Becker muscular dystrophy, a muscle-weakening disease. About 260 adults and teens who were in earlier EDG-5506 studies will take the drug and be monitored for side effects a…
Phase 2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New obesity drug shows promise in major trial
Disease control OngoingThis study tests a new drug called maridebart cafraglutide to help adults with obesity or overweight lose weight. About 3853 people will take either the drug or a placebo for 72 weeks. The main goal is to see how much weight they lose and if it is safe.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New eye injection aims to slow genetic blindness
Disease control OngoingThis study tests a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that damages the optic nerve (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose,…
Phase 1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis early-stage trial tests whether combining two drugs, ceritinib and nivolumab, is safe and effective for people with a specific genetic subtype of advanced lung cancer called ALK-positive NSCLC. About 57 adults with stage IIIB or IV disease will receive the combination. The m…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill takes on rare salivary gland and colon cancers
Disease control OngoingThis early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…
Phase 1 • Sponsor: Rgenta Therapeutics Inc • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Virus plus radiation may shrink sarcomas before surgery
Disease control OngoingThis study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for kids with Drug-Resistant TB: bedaquiline trial launches
Disease control PausedThis study tests a drug called bedaquiline in children and teens (0 months to under 18 years) with multidrug-resistant tuberculosis (MDR-TB), a lung infection that does not respond to standard antibiotics. About 60 participants will receive bedaquiline along with other TB medicat…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Immunotherapy added to standard treatment aims to stop esophageal cancer from returning
Disease control OngoingResearchers are testing whether adding the immunotherapy drug camrelizumab to chemotherapy or chemoradiotherapy before surgery helps people with locally advanced esophageal squamous cell carcinoma. The trial enrolls adults with resectable tumors who have not received prior treatm…
Phase 3 • Sponsor: Zhigang Li • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Brain cancer trial: one big dose or several small doses of radiation?
Disease control OngoingThis phase III trial tests whether giving several small doses of radiation (fractionated radiosurgery) after removing a brain tumor is better than a single large dose. About 242 patients with cancer that spread to the brain will be randomly assigned to one of the two radiation pl…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for dravet syndrome: phase 3 trial of LP352 aims to cut seizure frequency
Disease control OngoingThis study tests whether the drug LP352 can safely reduce seizures in children and adults with Dravet syndrome, a severe form of epilepsy. About 160 participants will receive either LP352 or a placebo, and researchers will track changes in seizure frequency over several months. T…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to stall rare Cancer's spread
Disease control OngoingThis study compares the drug palbociclib alone versus palbociclib plus cemiplimab in 77 people with advanced dedifferentiated liposarcoma that cannot be removed by surgery. Palbociclib blocks enzymes that help cancer cells grow, while cemiplimab boosts the immune system to attack…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo targets CD46 in aggressive prostate cancer
Disease control OngoingResearchers are testing a new drug called FOR46, which seeks out a protein called CD46 on cancer cells, together with enzalutamide, a standard hormone therapy, in men whose prostate cancer has spread and worsened despite prior treatment with abiraterone. The trial aims to find th…
Phase 1/2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can special lenses plus eye drops stop Kids' myopia from getting worse?
Disease control OngoingThis study tests whether combining special glasses (that create optical defocus) with low-dose atropine eye drops can better control myopia (nearsightedness) in children aged 7 to 12. Over 18 months, researchers will measure changes in eye prescription and eye length. The goal is…
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a daily injection save your sight? new trial for dry AMD
Disease control OngoingThis phase 3 trial tests whether a daily injection of elamipretide can slow vision loss in people with dry age-related macular degeneration (AMD). About 313 adults aged 55 and older with early dry AMD will receive either the drug or a placebo for 96 weeks. The main goal is to see…
Phase 3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Chemotherapy delivered directly to abdomen shows promise in early trial
Disease control OngoingThis early-phase trial tests a combination of three drugs for people whose appendix or colon cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). After surgery to remove visible tumors, patients receive chemotherapy directly into the abdomen (oxaliplatin) p…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug aims to tame rare bleeding disorder
Disease control OngoingThis study tests a new medicine called ALN-6400 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. First, healthy volunteers will receive a single dose to check safety. Then, HHT patients will recei…
Phase 1/2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered immune cells take aim at CD70-Positive cancers in new trial
Disease control CancelledThis early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Liver tumor treatment gets a targeted boost: Drug-Loaded beads take aim at metastases
Disease control OngoingThis early-phase trial is testing a new approach for people with liver metastases (cancer that has spread to the liver from elsewhere). Doctors are using a procedure called TACE to deliver the drug bevacizumab directly into the liver's blood vessels, aiming to concentrate the tre…
Phase 1/2 • Sponsor: Pardis Noor Medical Imaging and Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Promising drug may shrink inoperable tumors in kids with rare genetic condition
Disease control OngoingThis study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors. Participants take the dru…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Crohn's: experimental drug targets gut inflammation
Disease control OngoingThis study tests an experimental drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Partic…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a simple ketone drink reduce the need for surgery in FAP patients?
Disease control By invitation onlyThis study tests whether a daily ketone supplement (BHB) is safe and tolerable for people with Familial Adenomatous Polyposis (FAP), a genetic condition that causes many colon polyps and often leads to surgery. Twenty participants will take the supplement for two weeks to see if …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of rare immune disorders
Disease control OngoingThis study is testing the long-term safety of a drug called leniolisib in people with primary immunodeficiency disorders linked to PI3K signaling. Participants are 12 people who already took leniolisib in a previous study and may benefit from continuing it. The goal is to see if …
Phase 2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill could outperform current KRAS lung cancer drugs
Disease control OngoingThis phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a Sugar-Blocking pill boost immunotherapy for tough cancers?
Disease control OngoingThis phase 2 trial tests whether adding an experimental pill (GB1211) to the immunotherapy drug pembrolizumab (Keytruda) works better than Keytruda alone for people with advanced melanoma or head and neck cancer. The study will enroll 92 participants and measure how many patients…
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hip implant aims to fix cartilage without replacement
Disease control OngoingThis early study is testing a new device called the ReNew Hip Implant in 15 people aged 14 to 64 with hip cartilage damage from conditions like osteoarthritis or hip impingement. The implant is surgically placed to repair the cartilage. Researchers are checking if it is safe and …
Sponsor: Cytex Therapeutics, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New daily injection could cut bleeding episodes in hemophilia
Disease control OngoingThis study tests a medicine called concizumab for people with hemophilia A or B who do not have inhibitors. The goal is to see if a daily shot under the skin can prevent bleeding episodes safely. About 156 participants, aged 12 and older, will either start concizumab right away o…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Radiation boosts liver size, paving way for cancer surgery
Disease control OngoingThis study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…
Sponsor: Northwestern University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Four-Drug cocktail aims to tackle tough myeloma
Disease control OngoingThis phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants ha…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Experimental drug TAK-243 targets tough blood cancers in early trial
Disease control OngoingThis early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for stomach cancer: targeted combo therapy enters final trial phase
Disease control OngoingThis study tests a new drug called ASKB589 combined with chemotherapy and an immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The trial includes 780 participants whose tumors have a specific marker (CLDN18.2). The goal is to see …
Phase 3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New obesity drug trial aims for 25% weight loss with gentler dosing
Disease control OngoingThis study tests a new medicine called NNC0662-0419 in 230 adults with obesity (BMI 30 or higher). Researchers want to see if different ways of increasing the dose over time can reduce stomach side effects while still helping people lose at least 25% of their body weight. The stu…
Phase 2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat brain cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an HDAC inhibitor wipe out residual leukemia cells?
Disease control OngoingResearchers are studying whether the drug chidamide can help keep high-risk acute myeloid leukemia (AML) in remission when used as maintenance therapy. The trial enrolls adults with specific genetic features and measurable residual disease who are not receiving a stem cell transp…
Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can myeloma treatment work without steroids?
Disease control OngoingResearchers are testing whether daratumumab and lenalidomide can treat newly diagnosed multiple myeloma without adding steroids. The trial enrolls patients who are not candidates for high-dose chemotherapy and have not received prior treatment. The goal is to see how often infusi…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Radiation probe targets Hard-to-Treat tumors
Disease control By invitation onlyResearchers are testing a new molecular probe called 177Lu-NI-FAPI that aims to deliver radiation directly to tumor cells. The probe targets two features common in aggressive tumors: low oxygen levels and fibroblast activation proteins. The study enrolls up to 20 adults with adva…
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug may help lung damage after stem cell transplants
Disease control OngoingThis study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most eff…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Lung cancer radiation gets a precision boost: trial aims to hit tumors harder, spare healthy tissue
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Universal donor immune cells tested against tough childhood cancer
Disease control OngoingResearchers are testing whether natural killer (NK) cells from a universal donor can be safely given with standard chemotherapy drugs and an immune-targeting antibody to children and young adults with neuroblastoma that has returned or stopped responding. The NK cells are modifie…
Phase 1/2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Blood test showdown: MCV vs. ferritin in iron overload treatment
Disease control OngoingThis study looks at whether the MCV test (which measures red blood cell size) is as good as or better than the standard ferritin test for guiding phlebotomy (blood removal) therapy in people with hereditary hemochromatosis, a condition causing too much iron absorption. About 622 …
Phase 2 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug duo targets rare kidney cancer in early trial
Disease control OngoingThis study tests a combination of two drugs (fruquintinib and serplulimab) as the first treatment for people with a rare type of kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will t…
Phase 2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New cocktail targets tough lymphoma
Disease control OngoingThis early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in people with mantle cell lymphoma that has returned or not responded to prior treatment. The main goal is to find the safest dose of this combination by monitoring side effects. U…
Phase 1 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for tough hodgkin lymphoma: immune drugs tested alone or together
Disease control OngoingThis study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if giving these drugs alone or together can shrink tumors. The trial involves 13 adults with measu…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to extend life in tough bladder cancer cases
Disease control OngoingThis study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Sound waves vs. prostate cancer: new MRI-Guided treatment tested
Disease control PausedThis study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…
Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo targets deadly brain cancer in early trial
Disease control OngoingThis early-phase study tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 36 adults with specific tumor types (MGMT methylated or unmethylated) will receive differ…
Phase 1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for older leukemia patients with gentler drug combo
Disease control OngoingThis study tests a new two-drug combination (ASTX727 and venetoclax) in adults with acute myeloid leukemia who are 75 or older, or have health issues that make standard strong chemotherapy too risky. The goal is to see if the drugs work well together and can control the leukemia.…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise for rare skin cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, …
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Drug could slash surgeries for rare airway disease
Disease control OngoingThis phase II trial tests whether bevacizumab, a drug that blocks blood vessel growth, can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants receive 11 doses of t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can adding linperlisib to standard chemotherapy improve outcomes in rare T-Cell lymphoma?
Disease control OngoingResearchers are testing whether adding the experimental drug linperlisib to standard CHOP chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma. The trial enrolls about 44 participants who have not received prior treatment. Everyone receives six cycles of the …
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for hard-to-treat lung cancer: experimental drug targets MET gene
Disease control OngoingThis study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a Telomere-Targeting drug revive immunotherapy in lung cancer?
Disease control OngoingThis phase 2 trial tests a new drug called THIO, which targets telomeres in cancer cells, followed by the immunotherapy cemiplimab (LIBTAYO) in people with advanced non-small cell lung cancer. The study includes about 227 participants whose cancer has progressed after initial tre…
Phase 2 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New study tests aggressive BP management to protect heart and kidneys in cancer patients
Disease control OngoingThis phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants a…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New stem cell approach aims to cure rare immune disease
Disease control OngoingThis study tests a high-dose stem cell transplant for people with chronic granulomatous disease (CGD), a condition that weakens the immune system. Participants receive donor stem cells along with drugs to prevent rejection and graft-versus-host disease. The goal is to improve tra…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise for leukemia patients
Disease control OngoingThis study tests a combination of four drugs (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) as the first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific genetic marker (mutated IGHV gene). The goal is to see if this combo can achieve…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a daily pill boost blood counts in fanconi anemia?
Disease control OngoingFanconi anemia is a genetic condition that can damage bone marrow and lead to low blood cell counts, causing anemia, bleeding, or infections. Researchers are testing whether a daily pill called eltrombopag can improve blood counts in people with this condition. The trial enrolls …
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an oral HER2 drug boost Chemo's punch in HER2-Low breast cancer?
Disease control OngoingResearchers are testing whether adding pyrotinib, an oral drug that targets HER2-family proteins, to standard chemotherapy helps shrink HER2-low, hormone receptor-positive breast cancer before surgery. The trial enrolls about 48 women with early or locally advanced disease. Every…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat mesothelioma
Disease control OngoingThis phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…
Phase 2 • Sponsor: Hyogo Medical University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Virus therapy joins Chemo-Radiation in fight against rectal cancer
Disease control OngoingThis early-phase trial tests a new treatment called NG-350A, a virus designed to stimulate the immune system inside tumors, combined with standard chemoradiotherapy for people with locally advanced rectal cancer. The study aims to see if this combination can improve the chance of…
Phase 1 • Sponsor: Akamis Bio • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
PET scans guide Nivolumab-Chemo combo in relapsed hodgkin lymphoma
Disease control OngoingResearchers test a treatment plan for adults with Hodgkin lymphoma that has come back or stopped responding to initial therapy. Participants receive nivolumab, an immunotherapy, plus three chemotherapy drugs. PET scans help doctors decide how much treatment each person needs. The…
Phase 1/2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can breast radiation be cut from three weeks to one?
Disease control CancelledResearchers compare two schedules of partial breast irradiation after breast-conserving surgery in women with low-risk early breast cancer. One group receives radiation daily for one week, the other for three weeks. The trial measures breast appearance three years later and track…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Antibody-Like drug joins forces with standard chemo to fight lung cancer
Disease control OngoingThis early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise against tough breast cancer
Disease control OngoingThis Phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug in 28-day cycle…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Cancer drug cabozantinib takes on rare, Fast-Growing tumors
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in 35 people with high-grade neuroendocrine tumors that have worsened after at least one prior treatment. These are rare, fast-growing cancers with limited options. The study aims to see if cabozantinib can shrink tumors or slow thei…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Triple drug combo aims to slow HR+/HER2- advanced breast cancer
Disease control OngoingResearchers are testing whether adding apatinib, a drug that blocks blood vessel growth, to a CDK4/6 inhibitor and hormone therapy helps control HR+/HER2- advanced breast cancer. The trial enrolls women aged 18 to 75 with confirmed HR-positive, HER2-negative invasive breast cance…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a natural compound in food help beat knee implant infections?
Disease control PausedThis trial tests whether a dietary supplement called protocatechuic acid (PCA) can improve health markers in people undergoing revision surgery for a knee prosthetic joint infection. Participants take PCA before and after surgery, and researchers measure changes in immune and met…
Sponsor: Dr. Dean Reeves Clinic • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials
Disease control OngoingThis early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…
Phase 1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo shows promise for chinese men with advanced prostate cancer
Disease control OngoingThis phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it…
Phase 3 • Sponsor: Astellas (Beijing) Pharmaceutical R&D Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Spinal gene injection aims to slow duchenne in toddlers
Disease control OngoingThis early-stage study tests a single injection of a gene therapy called INS1201, given into the spinal fluid of young boys (ages 2 to 5) with Duchenne muscular dystrophy who can still walk. The main goal is to check if the treatment is safe and to see how it spreads in the body.…
Phase 1 • Sponsor: Insmed Gene Therapy LLC • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug takes aim at ovarian cancers that resist platinum chemotherapy
Disease control OngoingResearchers are testing an experimental drug called IBI354 in people with ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The trial compares IBI354 given alone with one of four standard chemotherapy drugs chosen by…
Phase 3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
A scanner in the operating room could show surgeons exactly where prostate cancer remains
Diagnosis OngoingSurgeons removing a prostate for cancer can struggle to tell cancerous tissue from healthy tissue, and cancer left at the edge of the removed gland is usually found only days later under a microscope. This pilot study at Geneva University Hospitals tests whether a PET/CT scanner …
Sponsor: University Hospital, Geneva • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Could MRI make CT scans obsolete for thymoma patients?
Diagnosis OngoingThis study compares MRI scans to standard CT scans for staging thymoma, a rare chest tumor. Researchers want to see if MRI can detect tumor spread just as well or better, without using radiation. Forty adults with newly diagnosed or recurrent thymoma will undergo both scans befor…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Self-sampling for cervical cancer screening could make testing easier and more accessible
Diagnosis OngoingThis study tests whether offering a self-sampling HPV test at a clinic increases the number of women who get screened for cervical cancer. Women who are due for screening can choose between a self-sampled test, a clinician-sampled test, or no screening. The study measures how man…
Sponsor: Milton S. Hershey Medical Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Contrast-Enhanced mammography: sharper images to catch hidden breast cancers?
Diagnosis OngoingThis study tests whether contrast-enhanced mammography (CEM) — a mammogram with an iodine dye injection — can find breast cancer more accurately than standard mammography. Researchers will compare CEM with other imaging methods in 100 women who have suspicious breast findings and…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Dry swabs could simplify HPV screening
Diagnosis PausedResearchers compare two ways to collect vaginal samples for high-risk HPV testing: swabs stored dry and swabs stored in liquid. The study enrolls 1,306 women aged 30 and older who have abnormal cervical screening results. The goal is to see if dry swabs detect HPV as accurately a…
Sponsor: Foundation for Innovative New Diagnostics, Switzerland • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Home antibody tests put to the test: can you read your own COVID-19 result?
Diagnosis CancelledResearchers are studying whether people can accurately use a rapid COVID-19 antibody test at home. Participants in New York City who have recovered from or suspect they had COVID-19 take the finger-prick test themselves and photograph the result for a doctor to check. The study a…
Sponsor: ProofPilot • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Light-Based probe aims to spot thyroid cancer faster
Diagnosis CancelledResearchers are testing a technique called Raman spectroscopy to see if it can accurately identify thyroid cancer in tissue samples. The study involves patients who are already having a routine thyroid biopsy for suspected cancer. After the biopsy, the removed tissue is examined …
Sponsor: Gloucestershire Hospitals NHS Foundation Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Blood thinner flush could boost tumor biopsy success
Diagnosis CancelledResearchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New PET tracer could sharpen sarcoma detection
Diagnosis OngoingThis early-phase trial tests a radioactive tracer called 68Ga-FAPI-46 to see where it collects in the body of people with sarcoma. Participants receive the tracer and undergo a PET/CT scan, which combines a detailed anatomical image (CT) with a functional image (PET) that highlig…
Early phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a simple score spot hidden gallbladder cancer?
Diagnosis OngoingResearchers are studying whether they can predict which patients having routine gallbladder removal for gallstones or related problems might have unsuspected gallbladder cancer. They plan to collect data from up to 30,000 adults and use risk factors to build a scoring system. The…
Sponsor: University Hospital Plymouth NHS Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a One-Stop clinic solve the mystery of functional disorders?
Diagnosis OngoingFunctional somatic disorders cause persistent physical symptoms that doctors cannot explain by other diseases. The DISTRESS trial evaluates a new clinic where internal medicine doctors, trained to recognize these disorders, examine patients and provide guidance to their general p…
Sponsor: Regionshospitalet Silkeborg • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Pee test could replace scope for bladder cancer checks
Diagnosis OngoingThis study is testing a simple urine test called CxBladder to see if it can accurately detect when bladder cancer comes back. Currently, patients need a camera inserted into the bladder (cystoscopy) for monitoring, which is uncomfortable and costly. The study will collect urine s…
Sponsor: Pacific Edge Limited • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can MRI spot which prostate cancers are safe to watch?
Diagnosis By invitation onlyResearchers at Herlev Hospital are studying whether multiparametric MRI can help doctors decide which men with low-risk prostate cancer can safely stay on active surveillance instead of getting treatment. The trial enrolls 150 men with newly diagnosed low-risk prostate cancer who…
Sponsor: Herlev Hospital • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New MRI technique could help men with prostate cancer avoid unnecessary treatment
Diagnosis By invitation onlyThis study is testing whether a special type of MRI (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely delay treatment. About 200 men already on active surveillance will receive the MRI, and if suspicious areas are found, they will get ad…
Sponsor: Herlev Hospital • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Can simple sputum and urine tests catch tuberculosis earlier?
Diagnosis OngoingResearchers are studying whether two tests, one on sputum and one on urine, can accurately detect tuberculosis in people suspected of having the infection. The trial enrolls 150 patients at tertiary care hospitals who can provide both sputum and urine samples. The goal is to see …
Sponsor: The HIV Netherlands Australia Thailand Research Collaboration • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Pee test may spare thousands from painful bladder scopes
Diagnosis OngoingThis study is testing a new, non-invasive urine test called Cxbladder Triage-Plus to see if it can accurately detect bladder cancer in people who have microscopic blood in their urine. Currently, these patients often need a cystoscopy, an invasive procedure where a camera is inse…
Sponsor: Pacific Edge Limited • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Tiny DNA fragments in blood could reveal how aggressive a pancreatic tumor will be
Diagnosis OngoingPancreatic neuroendocrine tumors behave unpredictably: some stay slow for years while others spread quickly, and doctors lack reliable tests to tell them apart before surgery. This study examines cell-free DNA, tiny genetic fragments shed by tumors into the bloodstream, from abou…
Sponsor: Massimo Falconi • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New scan could spot childhood cancer more clearly
Diagnosis CancelledThis study tests whether a new type of PET scan (18F-MFBG) can detect neuroblastoma tumors as accurately as the current standard scan (123I-MIBG). About 84 children and adults with newly diagnosed, high-risk neuroblastoma will receive both scans to compare results. If the new sca…
Phase 2 • Sponsor: Children's Oncology Group • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Digital tool aims to keep kids healthy: 1,400 children test new obesity prevention program
Prevention OngoingThis study tests a digital health platform delivered through WeChat to prevent obesity in 1,400 school children in grades 2 and 3. The program includes health education, growth monitoring, behavior tracking, and home-school partnerships. Researchers will compare children using th…
Sponsor: Peking University • Aim: Prevention
Last updated Sep 21, 2026 13:01 UTC
-
New study aims to stop severe reactions to cancer infusion therapy
Prevention OngoingThis phase 2 study tests whether giving dexamethasone, montelukast, or methotrexate before an amivantamab infusion can reduce or prevent infusion-related reactions in people with a type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolled 68 partic…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Prevention
Last updated Sep 21, 2026 13:01 UTC
-
One shot to stop cancer: HPV vaccine study could change global prevention
Prevention OngoingThis study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …
Phase 4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Sep 21, 2026 13:00 UTC
-
Could a Plant-Based diet stop a blood cancer before it starts?
Prevention OngoingThis study tests whether a plant-based diet is practical for overweight people with MGUS or smoldering multiple myeloma, conditions that can lead to multiple myeloma. For 12 weeks, 23 participants receive two pre-made plant-based meals daily. Researchers track weight loss and die…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Sep 21, 2026 13:00 UTC
-
Monthly HIV prevention pill could replace daily dose
Prevention OngoingThis large phase 3 trial is testing whether a new oral pill called MK-8527, taken just once a month, can prevent HIV infection as well as the standard daily PrEP pill. About 4,390 people at risk of HIV will be randomly assigned to receive either the monthly pill or daily Truvada …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can a smaller dose of a white blood cell booster protect cancer patients just as well?
Prevention By invitation onlyResearchers are studying whether a lower 3mg dose of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can prevent febrile neutropenia, a serious drop in infection-fighting white blood cells, in cancer patients after chemotherapy. The standard 6mg do…
Sponsor: Zhejiang Provincial People's Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can natural mouthwashes fight cavity bacteria as well as chlorhexidine?
Prevention OngoingResearchers are testing three mouthwashes, licorice, clove, and chlorhexidine, in Egyptian children aged 7 to 12 who have a high risk of cavities. The trial measures levels of Streptococcus mutans, a bacterium linked to tooth decay, in saliva before and after children use their a…
Sponsor: British University In Egypt • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
One-Shot flu prevention? new drug aims to protect High-Risk groups all season
Prevention OngoingThis phase 3 trial is testing whether a single dose of CD388, a long-acting antiviral injection, can prevent the flu in 10,000 adults and teens at higher risk of complications. Participants receive either CD388 or a placebo and are monitored for flu-like illness over 24 weeks. Th…
Phase 3 • Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
How long do HPV vaccine antibodies last? a 11-Year Follow-Up aims to find out
Prevention OngoingResearchers are tracking HPV-16 and HPV-18 neutralizing antibodies in females who received a bivalent HPV vaccine in an earlier study. Participants were 9 to 26 years old when first vaccinated and received either two or three doses. No vaccine is given in this extension. Blood sa…
Sponsor: Shanghai Zerun Biotechnology Co.,Ltd • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Can testing together again keep male couples HIV-Free?
Prevention By invitation onlyResearchers are testing whether repeat couples HIV testing and counseling helps male couples at high risk of HIV. The study enrolls couples who already took part in an earlier testing program. Couples are assigned by chance to either retest together or to individual HIV testing. …
Sponsor: Hunter College of City University of New York • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Village health workers lead new HIV prevention effort in lesotho
Prevention CancelledThis study tests a new program where trained village health workers use tablet-based tools to provide HIV prevention services, including PrEP and emergency PEP, to people at high risk in rural Lesotho. About 380 participants will be enrolled to see if this approach increases mont…
Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Aspirin shows promise in blocking ovarian cancer for High-Risk women
Prevention OngoingThis study tests whether taking aspirin can prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 participants will take either aspirin or a placebo daily for up to 2 years before their scheduled risk-reducing surgery. Researchers wil…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Four weeks vs twelve weeks: can a shorter TB prevention course work?
Prevention OngoingResearchers are testing whether a 4-week daily course of isoniazid and rifapentine can prevent active tuberculosis as well as the standard 12-week weekly course in people with HIV who have latent TB infection. The trial enrolls about 2,500 adults in a high TB burden country. Both…
Phase 3 • Sponsor: The HIV Netherlands Australia Thailand Research Collaboration • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Global push to fight childhood obesity in poorer urban areas
Prevention By invitation onlyThis study tests community-based programs in six countries to help children ages 6-13 eat healthier and be more active. The goal is to prevent obesity and improve quality of life in disadvantaged urban communities. Researchers will track changes in body mass index and health-rela…
Sponsor: Novo Nordisk A/S • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Malaria vaccine trial for pregnant women launches in mali
Prevention CancelledThis Phase 1 trial in Mali will test the safety of the PfSPZ malaria vaccine in 400 healthy pregnant women aged 18-34. Participants will receive three injections of either the vaccine or a placebo. The study will monitor both mothers and their infants for up to a year after birth…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
New hope: natural compound may stop chemo nerve pain
Prevention OngoingThis study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can schools teach kids to love Heart-Healthy habits?
Prevention OngoingResearchers are testing a school program that teaches children about healthy eating, physical activity, and sleep to improve heart health. The trial involves 840 children in 50 elementary schools in Spain. Schools are assigned to either start the program in 2nd grade with a boost…
Sponsor: Foundation for Science, Health and Education, Spain • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can a School-Family-Hospital program keep kids healthy?
Prevention OngoingThis study tests a program that uses kindergartens, families, and hospitals to prevent obesity in children aged 4-6. About 980 children in China will take part. The program includes teacher training, health lessons, parent education, and check-ups. Researchers will measure change…
Sponsor: Peking University • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Peer power: could support groups boost HIV prevention in transgender men?
Prevention OngoingThis study tests whether peer-led support—either one-on-one, in a group, or both—can help transgender men who have sex with men start and continue taking PrEP, a daily pill that prevents HIV. Participants are randomly assigned to receive standard HIV prevention information, a tai…
Sponsor: Fenway Community Health • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can a smartphone app calm lung cancer surgery nerves?
Symptom relief OngoingThis pilot study tests whether a smartphone app called AmDTx can help lung cancer patients manage anxiety before and after surgery. The app includes mindfulness training and a relaxing puzzle game. Only 6 participants are enrolled, and the main goal is to see if people will actua…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 21, 2026 13:01 UTC
-
Brain and body boost: Dual-Task training may ease Parkinson's symptoms
Symptom relief By invitation onlyThis study tests whether adding cognitive training to balance and gait exercises helps people with Parkinson's disease improve their balance, walking, and thinking. Fourteen participants will undergo 12 sessions of combined training. The goal is to see if this approach eases move…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Sep 21, 2026 13:01 UTC
-
Could fasting before immunotherapy boost skin cancer treatment?
Symptom relief OngoingThis early study tests whether short-term fasting (eating less than 200 calories per day for 3 days) before standard immunotherapy is safe and doable for people with advanced or metastatic skin cancer. Ten participants will receive their usual PD-1/PD-L1 inhibitor drugs along wit…
Phase 1 • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Sep 21, 2026 13:00 UTC
-
Hypnosis may calm cancer patients during radiation
Symptom relief OngoingThis study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Sep 21, 2026 13:00 UTC
-
Hands-On therapy put to the test for spine and jaw pain
Symptom relief By invitation onlyResearchers at Poznan University of Physical Education are studying whether physiotherapy and osteopathic techniques ease pain in the neck, lower back, and jaw. The trial enrolls 300 adults aged 20 to 40 who have a recent episode of neck or lower back pain lasting no more than si…
Sponsor: Poznan University of Physical Education • Aim: Symptom relief
Last updated Sep 21, 2026 13:00 UTC
-
Phone therapy shows promise for depression in ovarian cancer patients
Symptom relief OngoingThis study looks at whether weekly phone counseling can help identify and treat depression in women with ovarian, peritoneal, or fallopian tube cancer. About 409 participants will either receive phone counseling or standard care with resource lists. The goal is to see which appro…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Custom knee guides put to the test in obese patients
Symptom relief OngoingResearchers are comparing two ways to perform total knee replacement in patients with obesity and knee arthritis. One method uses custom-made guides based on each patient's knee scans, while the other uses standard surgical tools. The trial measures how well the knee aligns, how …
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Home workouts may help endometrial cancer survivors shed pounds
Symptom relief OngoingThis study tests whether a home-based weight loss program, with or without resistance training, is practical for endometrial cancer survivors. Fifteen participants will follow a program using a workbook, fitness tracker, and coaching calls. The goal is to see if they can lose wei…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Could two weeks of radiation be as good as six for this brain cancer?
Symptom relief OngoingThis study is for people with a rare and aggressive brain tumor called diffuse midline glioma. Instead of the usual six weeks of daily radiation, researchers are testing a shorter course of just two weeks. The goal is to see if the shorter treatment works just as well at controll…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Online course aims to boost diet and Self-Care for MS and fatigue patients
Symptom relief OngoingThis study is testing whether an online course can help people with multiple sclerosis, long COVID, fibromyalgia, or cancer-related fatigue adopt healthier diets and self-care habits. Researchers will measure changes in quality of life, fatigue, and mental health. The goal is to …
Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Exercise and diet may ease fatigue in CLL patients
Symptom relief OngoingThis study looks at whether exercise and weight management can help reduce fatigue in people who have had chronic lymphocytic leukemia (CLL). About 30 adults aged 18-85 with CLL will take part. Participants will be randomly assigned to start the program right away or after a wait…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Suture device may get heart patients walking sooner after leg vein procedures
Symptom relief By invitation onlyResearchers are testing whether a suture-based closure device helps patients recover faster after heart procedures that use a large tube placed in the femoral vein. The trial enrolls adults undergoing procedures such as atrial fibrillation ablation, leadless pacemaker insertion, …
Sponsor: Ewha Womans University Mokdong Hospital • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Massage may ease chemo nerve damage
Symptom relief OngoingThis study looks at whether massage therapy can reduce nerve problems like pain, numbness, and tingling caused by chemotherapy in people with breast or digestive system cancers. About 90 participants will receive massage sessions to see if it improves symptoms and quality of life…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a video-based therapy tame tough behaviors in kids with rare genetic disorders?
Symptom relief OngoingThis study tests a virtual behavioral therapy (Functional Behavioral Training) for children aged 2-12 with genetic syndromes like Fragile X, Angelman, or Rett syndrome who have challenging behaviors. The therapy teaches parents how to identify what triggers problem behaviors and …
Sponsor: Rush University Medical Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
One shot of radiation may ease cancer symptoms as well as multiple sessions
Symptom relief OngoingThis study compares a single session of palliative radiation therapy to the standard multiple sessions for people with gynecologic cancers that have spread. The goal is to see if one treatment can improve symptoms like pain and bleeding and boost quality of life just as well. Abo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Mind over scalpel: Self-Hypnosis may ease Post-Surgery pain for cancer patients
Symptom relief OngoingThis study looks at whether listening to a self-hypnosis audio before surgery can help women with gynecologic cancer feel less pain and recover faster. About 152 patients having surgery for cancers of the female reproductive system will be randomly assigned to either usual care o…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Hidden braces aim to straighten tilted back molars
Symptom relief CancelledResearchers at Hanoi Medical University are studying whether small lingual appliances can correct an excessive Curve of Wilson at the lower second molars in people already wearing labial fixed braces. The trial uses a split-mouth design: one side of the mouth receives the auxilia…
Sponsor: Hanoi Medical University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can surgeons spare nerves and still cure colon cancer?
Symptom relief OngoingDoctors remove right or left colon cancer along with nearby lymph nodes, but the deep nerves that control the gut often get damaged. That damage can leave patients with lasting diarrhea, bowel spasms, or slow bowel movements. This trial compares standard surgery with a laparoscop…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could a 4-Hour infusion replace 20 hours for neuroblastoma kids?
Symptom relief OngoingThis study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …
Phase 2 • Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can mindfulness ease cancer stress for latino families?
Symptom relief OngoingThis study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
A bag that holds the small intestine could change colon surgery
Symptom relief By invitation onlyDuring laparoscopic surgery on the rectum or lower sigmoid colon, the small intestine can slip into the operating area and block the surgeon's view. This trial tests a disposable isolation device that holds the small intestine away from the surgical site. Researchers compare the …
Sponsor: Beijing Friendship Hospital • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Mindfulness program aims to ease lung cancer breathlessness
Symptom relief OngoingThis study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …
Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could peppermint oil be a natural pain reliever for fibromyalgia?
Symptom relief By invitation onlyThis study is testing whether applying peppermint oil to the skin can reduce chronic pain and improve daily function in people with fibromyalgia. Researchers will also look at whether this treatment is cost-effective compared to standard care. About 175 adults with fibromyalgia w…
Sponsor: Bilecik Seyh Edebali Universitesi • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Giving Parkinson's patients a say may boost their Brain's ability to learn movement
Symptom relief OngoingPeople with Parkinson's disease often struggle with motivation and motor learning, which can limit rehabilitation. This trial compares two ways of practicing a joystick task: one group chooses the stories and exercises they practice, while the other follows the same routine witho…
Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Dental implant showdown: titanium vs nano-carbon frames
Symptom relief OngoingResearchers compare two materials for the framework that supports a full set of replacement teeth on four dental implants in the lower jaw. Ten completely edentulous patients receive either a titanium or a nano-carbon fiber-reinforced CAD/CAM framework. The study tracks gum healt…
Sponsor: Mansoura University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New study tracks how well thyroid ablation eases symptoms
Symptom relief By invitation onlyThis Mayo Clinic study tracks 300 patients undergoing radiofrequency ablation for symptomatic thyroid nodules. Researchers use a simple questionnaire to measure changes in symptoms like discomfort or swallowing issues before and after the procedure. The goal is to better understa…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can red light therapy boost your hormones?
Symptom relief CancelledResearchers are testing whether an 8-week course of Joovv infrared light therapy can change hormone levels in healthy adults. The study measures testosterone in men and estrogen, progesterone, and thyroid-stimulating hormone in women, along with general wellness. Participants use…
Sponsor: ProofPilot • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a website help liver cancer patients care for themselves during chemoembolization?
Symptom relief OngoingResearchers are testing whether an enhanced web-based health education program helps people with hepatocellular carcinoma (liver cancer) improve their self-care and quality of life while undergoing transarterial chemoembolization (TACE). The trial enrolls 252 adults scheduled for…
Sponsor: University Medical Center Ho Chi Minh City (UMC) • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a Hands-On nerve technique ease Fibromyalgia's grip?
Symptom relief By invitation onlyResearchers in Chile are testing whether adding neural mobilization, a physical therapy technique that targets nerve movement, to standard fibromyalgia care improves daily function and reduces pain more than standard care alone. The trial enrolls 20 women aged 18 and older with a…
Sponsor: Pontificia Universidad Catolica de Chile • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Legal aid may ease burden for cancer caregivers
Symptom relief OngoingThis pilot study offers free legal services to caregivers and patients dealing with advanced colorectal cancer. The goal is to see if early legal support can reduce financial and emotional stress. Twenty patient-caregiver pairs will receive personalized legal help from a nonprofi…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New shot aims to quiet chemo nerve pain
Symptom relief OngoingThis study tests an injected drug called Halneuron to see if it can safely reduce nerve pain caused by chemotherapy. About 240 adults who have nerve pain from platinum or taxane chemo will receive either Halneuron or a placebo shot. The goal is to measure pain relief, sleep, fati…
Phase 2 • Sponsor: Dogwood Therapeutics Inc. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to ease mental health struggles and stigma for young HIV-positive men in vietnam
Symptom relief OngoingThis study adapts Project YES+, a behavioral program, to improve mental health and reduce HIV-related stigma for adolescent and young men who have sex with men living with HIV in Vietnam. Eighty participants aged 16-24 will receive individual and group sessions with peer mentors.…
Sponsor: Hanoi Medical University • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Could a social media app help heal the emotional scars of cancer?
Symptom relief By invitation onlyThis trial tests whether a program designed to boost social connections can improve the social and emotional well-being of young adults who had cancer. Participants, aged 22-39 and diagnosed between 15-39, will receive a video and planning tools to encourage more in-person intera…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
One-Day liver cancer treatment shows promise in early trial
Symptom relief OngoingThis early-phase study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in a single session instead of the usual two-day process. The treatment uses tiny radioactive beads injected into the liver's blood supply to block tumor growth. Research…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Custom-Shaped nose splint may ease recovery for kids after cleft lip surgery
Symptom relief By invitation onlyChildren who have cleft lip repair or nasal scar release often wear a nasal splint while healing. This trial compares the standard hollow, cone-shaped conformer with a new one shaped to match the inside of the nose. Each child tries both types, switching halfway through, and pare…
Phase 2 • Sponsor: East Tennessee Children's Hospital • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can a personalized mix of nerve stimulation and therapy rewire the brain for better mental health?
Symptom relief OngoingResearchers are testing a personalized, non-drug treatment for adults with ongoing depression, anxiety, trauma-related symptoms, sleep problems, attention difficulties, or substance-use concerns. Instead of assigning treatment by diagnosis alone, the study selects approaches base…
Sponsor: Tactical Mind Research Coalition, Inc. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Needle in the spine: new hope for cancer pain?
Symptom relief OngoingThis study tests a procedure called cordotomy, where a needle is guided into the spinal cord to block pain signals. It's for people with advanced cancer who have severe pain on one side of the body below the shoulder. The goal is to see if it reduces pain better than a fake proce…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New radiation approach may spare thinking skills in brain cancer patients
Symptom relief OngoingThis study compares two radiation treatments for people whose non-melanoma cancer has spread to the brain with 4 to 15 tumors. One method, stereotactic radiosurgery, delivers a high dose only to the tumors, while the other treats the whole brain. The goal is to see which better c…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Steroid rinse inside the tooth: a new way to curb root canal pain?
Symptom relief OngoingThis trial compares two final rinses used during two-visit root canal treatment for adults with symptomatic irreversible pulpitis, a painful tooth infection. Participants receive either a dexamethasone solution or normal saline as the last rinse inside the root canal. Researchers…
Sponsor: CMH Lahore Medical College and Institute of Dentistry • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Splint showdown: which brace best beats trigger finger?
Symptom relief By invitation onlyResearchers compare two splint designs to see which better eases trigger finger, a condition where a finger catches or locks when bent. Thirty people with trigger finger wear either a metacarpophalangeal joint blocking splint or a relative motion extension splint. The study measu…
Sponsor: Waikato Hospital • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Brain scans reveal secrets of lost smell
Knowledge-focused By invitation onlyThis study tracks 80 adults with different smell disorders (like total loss, partial loss, or distorted smell) plus healthy volunteers over one year. Researchers use brain scans, smell tests, and questionnaires to see how the brain changes and how smell loss impacts mood and dail…
Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD) • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:01 UTC
-
Do factory workers know how to stay hydrated and eat well? a large survey aims to find out.
Knowledge-focused By invitation onlyThis study uses surveys to assess the hydration and nutrition habits and knowledge of frontline workers in PepsiCo manufacturing facilities. Researchers will measure understanding of hydration principles, actual drinking behaviors, and dietary patterns using validated questionnai…
Sponsor: PepsiCo Global R&D • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:01 UTC
-
Late meals, Off-Beat sleep: could timing be key to weight control?
Knowledge-focused OngoingThis study looks at how eating and sleeping at mismatched times (like shift workers do) affects weight regulation. Researchers will track 42 adults with overweight or obesity, measuring energy use, body composition, and brain responses to food. The goal is to understand whether a…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:01 UTC
-
Simple test may predict chemo risks for seniors with lymphoma
Knowledge-focused OngoingThis study looks at whether a self-administered geriatric assessment can help predict serious side effects in people aged 60 and older with Non-Hodgkin lymphoma who are starting chemotherapy. The goal is to see if this assessment can identify who is at higher risk for hospitaliza…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:01 UTC
-
Massive study digs into why some kids outgrow food allergies
Knowledge-focused By invitation onlyThis research study aims to understand why some people develop food allergies and others outgrow them. Researchers at Children's Hospital of Philadelphia will collect blood samples from 5,300 people (ages 1 month to 65 years) with and without food allergies to study immune cells …
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:01 UTC
-
New PET scan tracks immune response in melanoma patients
Knowledge-focused OngoingThis early-phase trial tested a special PET/CT imaging agent, Zirconium Zr 89 Crefmirlimab Berdoxam, to see if it can measure immune activity in tumors of patients with advanced melanoma. Six adults on immunotherapy plus hydroxychloroquine received scans before and after starting…
Early phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Massive study digs into Diet-Disease link
Knowledge-focused OngoingThis study looks at information already collected from over 566,000 AARP members aged 50 to 71. Researchers want to learn how diet and lifestyle choices are linked to cancer, chronic diseases, and death. No new participants are being recruited, and no treatments are being tested.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Dystonia study seeks to map Disease's Real-World toll
Knowledge-focused OngoingThis study watches 200 people with isolated dystonia (affecting more than one body part) to see how the condition changes over time. Researchers will collect information on symptoms, daily activities, pain, and social life using standard rating scales. No experimental treatment i…
Sponsor: Vima Therapeutics • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Heart drug entresto may double as diabetes treatment, small study hints
Knowledge-focused CancelledThis study tests whether a heart failure medication called Entresto (sacubitril/valsartan) can boost a natural hormone that helps control blood sugar after meals. Researchers will give the drug or a comparison drug (valsartan) to 25 adults with type 2 diabetes or prediabetes and …
Phase 3 • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Tiny hearts, tiny kidneys: new study monitors oxygen in preterm infants
Knowledge-focused OngoingThis study looks at oxygen levels in the kidneys of premature babies born before 32 weeks who have a heart condition called patent ductus arteriosus (PDA). Researchers want to see how kidney oxygen relates to the severity of the heart condition and whether it can predict kidney i…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Can a One-Page guide spark better End-of-Life talks for dementia patients?
Knowledge-focused OngoingThis study tests a short guide called the 'Jumpstart Guide' to help doctors have better conversations with dementia patients and their families about healthcare goals. Over 1,800 patients and their caregivers are taking part. Researchers will compare whether those whose doctors u…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Can brain recordings make DBS safer for thinking and memory?
Knowledge-focused OngoingThis study tracks brain activity in 160 Parkinson's patients who have or will receive deep brain stimulation (DBS). Researchers record signals from the brain during memory tasks, with the stimulator on and off, to find patterns linked to cognitive side effects. The goal is to ide…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Can tumor profiling help kids beat cancer? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Can phone coaching help hispanic seniors beat sedentary habits?
Knowledge-focused OngoingThis study enrolls 130 Hispanic adults aged 55+ without dementia to see if a 12-week phone-based coaching program helps them become more active. Participants are randomly assigned to either the coaching program or a general brain health education group. The goal is to see if the …
Sponsor: Kaiser Permanente • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Childhood farm life under the microscope: could pesticides raise cancer risk?
Knowledge-focused By invitation onlyThis study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Cancer cell therapy recipients monitored for years in new safety study
Knowledge-focused By invitation onlyThis study follows 1,000 people who previously received gene-modified cell therapies (like Yescarta or Tecartus) for blood or solid cancers. No new treatment is given. Researchers will watch for late side effects, growth in children, and overall survival. The goal is to better un…
Sponsor: Kite, A Gilead Company • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
Knowledge-focused By invitation onlyThis study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
New computer tool aims to boost HIV prevention in community clinics
Knowledge-focused OngoingThis pilot study tests whether an electronic health record tool can help doctors identify patients at higher risk for HIV and prescribe PrEP, a daily pill that prevents HIV. Researchers will roll out the tool in 2-3 community health centers and compare PrEP prescription rates to …
Sponsor: Harvard Pilgrim Health Care • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists track eye disease progression over five years
Knowledge-focused OngoingThis study follows 110 people who previously took part in the AREDS or AREDS2 trials to see how age-related macular degeneration (AMD) and cataracts change over time. Participants get a yearly eye exam, including vision tests and eye photos, and may give a blood sample. The goal …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
Knowledge-focused OngoingResearchers are running an international registry to follow adults who had an ischemic stroke or transient ischemic attack and also have a patent foramen ovale, a small opening between the upper chambers of the heart. The registry collects real-world information on how these pati…
Sponsor: Luciano A. Sposato • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New hope for myeloma patients: switching to ixazomib after failed treatments?
Knowledge-focused OngoingThis study follows 72 adults with multiple myeloma who switch from a bortezomib- or carfilzomib-based treatment to an ixazomib-based regimen. Researchers are tracking side effects and how long patients go without the disease getting worse. The goal is to see if this switch is a g…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a Pre-Surgery diet change help prostate cancer patients?
Knowledge-focused OngoingThis study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet before their surgery to remove the prostate. The goal is to see if this diet is practical and well-tolerated. Twelve participants will eat specially prepared meals and then unde…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
10-Year NF1 study aims to unlock secrets of rare genetic disorder
Knowledge-focused OngoingThis natural history study follows 259 children, adolescents, and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers will track tumor growth, monitor quality of life, and perform genetic testing to better understand how the disease changes over time. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gut bacteria may hold clues to why some cancer treatments work better
Knowledge-focused PausedResearchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists probe why junk food is so hard to resist
Knowledge-focused OngoingThis study looks at how different types of ultra-processed foods—like those high in fat, sugar, or both—affect feelings of reward and overeating. Fifty adults with obesity will eat various snack foods in the lab and report their cravings and mood. The goal is to understand what m…
Sponsor: Oregon Research Institute • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
NIH opens screening study to find candidates for blood disorder research
Knowledge-focused By invitation onlyThis study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Massive data collection aims to spark breakthroughs in blood disorders
Knowledge-focused By invitation onlyThis study gathers medical information from up to 10,000 people with blood or heart conditions, as well as stem cell donors, treated at the National Institutes of Health. Researchers will review participants' medical records, test results, and treatments to build a database for g…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Blood tests could reveal secrets of rectal cancer
Knowledge-focused OngoingThis study looks at tiny pieces of cancer cells or DNA floating in the blood of people with rectal cancer. Researchers want to see if these markers can help predict how the tumor responds to standard treatment. About 341 participants, including healthy volunteers, will provide bl…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a simple text reminder help catch lung cancer early?
Knowledge-focused OngoingThis study tests whether reminder messages can encourage people aged 40-80 who smoke or have smoked to get screened for lung cancer. Researchers will ask about 133 participants how acceptable they find these reminders. The goal is to see if this simple approach could help more pe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Education boosts genetic testing in black prostate cancer patients
Knowledge-focused OngoingThis pilot study aims to see if a brief educational session can increase the number of Black men with aggressive prostate cancer who complete genetic testing. Researchers will enroll 50 men who identify as Black or multiracial and have high-risk prostate cancer. Participants will…
Sponsor: Henry Ford Health System • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gene test may guide breast cancer therapy choices
Knowledge-focused OngoingThis study looks at whether a genetic test on tumor samples can predict how well HER2-negative breast cancer will respond to standard treatments like chemotherapy or hormone therapy. About 1,100 people with stage I-III breast cancer are taking part. The goal is to see if this tes…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Melanoma survivors: new study tracks immunotherapy side effects
Knowledge-focused OngoingThis study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
Knowledge-focused OngoingResearchers are studying HDM1005, an experimental injection for overweight and obesity, to see if the body absorbs it differently depending on where it is injected. The trial compares injections given in the upper arm and thigh against injections in the abdomen. About 135 healthy…
Phase 1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Pompe disease study aims to clear path for gene therapy
Knowledge-focused OngoingThis study looks at people with late-onset Pompe disease to measure antibodies against a virus used in gene therapy and against the standard enzyme replacement therapy. It also checks for biomarkers in blood and urine. About 119 teenagers and adults will give samples over 2 years…
Sponsor: Astellas Gene Therapies • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a smartphone app give prostate cancer patients more control?
Knowledge-focused By invitation onlyResearchers are studying whether a mobile health app called myAria helps adult prostate cancer patients track symptoms, share health data, and feel more empowered during treatment. Participants use the app to log side effects and well-being, complete questionnaires, and view a no…
Sponsor: Constantinos Zamboglou • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Radiation for 6+ brain tumors: how does it affect memory?
Knowledge-focused OngoingThis study looks at how precise radiation (stereotactic radiosurgery) affects memory and thinking in people with 6 or more brain tumors that have spread from other cancers. About 80 adults will take part to find the safest radiation dose and measure any decline in memory over 4 m…
Phase 1/2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gut microbes may hold key to why cancer immunotherapy works for some
Knowledge-focused By invitation onlyResearchers are building a bank of blood, urine, and stool samples from 100 adults with non-small-cell lung or colorectal cancer who are receiving checkpoint inhibitor immunotherapy. Over 12 months, participants provide five samples of each type. The goal is to study how the body…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New program aims to lift mood and boost treatment adherence in head and neck cancer
Knowledge-focused OngoingThis study tests a new program designed to help head and neck cancer patients who feel depressed. The goal is to see if the program is practical and liked by patients, and if it can improve their mood and help them follow through with swallowing exercises and dental care. About 1…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Biopsy vs. surgery: could some breast cancer patients avoid the knife?
Knowledge-focused OngoingThis study tests whether a less invasive ultrasound-guided biopsy can accurately tell if breast cancer has been completely wiped out by chemotherapy, compared to the standard method of checking during surgery. About 43 women with aggressive breast cancer types (triple negative or…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New tools aim to speed up FSHD drug trials
Knowledge-focused OngoingThis study involves 324 adults with facioscapulohumeral muscular dystrophy (FSHD) across 14 international sites. Researchers are testing two new measurement tools—a functional test called FSHD-COM and a muscle-impedance device—to better track disease progression. The goal is to i…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Blood samples sought to unlock secrets of sickle cell disease
Knowledge-focused By invitation onlyThis study collects blood and other samples from people with sickle cell disease and healthy volunteers to help researchers understand how inflammation affects blood vessels. Up to 2,000 adults aged 18 and older will take part. The samples will be used in lab tests to support fut…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Austrian study maps how lung, heart, and metabolic health interact
Knowledge-focused OngoingThe Austrian LEAD study follows a large group of people to understand how lung, heart, and metabolic health change over time. Researchers measure lung function with spirometry and track body composition and metabolic markers. By observing this group, they aim to learn how these c…
Sponsor: Ludwig Boltzmann Institute for Lung Health • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could a simple antibiotic dosing schedule be key to STI prevention?
Knowledge-focused By invitation onlyThis study looks at how the body processes doxycycline, an antibiotic, when taken in different ways—either as a single dose or repeated doses (daily or every three days). Healthy adults without any sexually transmitted infections will be randomly assigned to one of these schedule…
Phase 1 • Sponsor: HIV Prevention Trials Network • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists hunt for clues to drug resistance in advanced breast cancer
Knowledge-focused OngoingThis study follows 25 women with advanced breast cancer to understand why the drug palbociclib stops working over time. Researchers collect blood and tumor samples before and after the cancer progresses to look for genetic and chemical changes. The goal is not to treat the diseas…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
500 COVID survivors tracked to uncover lingering health mysteries
Knowledge-focused OngoingThis study follows 500 adults who had COVID-19 to see what health problems they face months later. Researchers will track symptoms like tiredness, breathing trouble, and lung damage. The goal is to learn how common these long-term issues are and who is most likely to have them.
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New tools could help doctors predict who will respond to chronic GVHD therapies
Knowledge-focused OngoingThis study involves 383 people who have chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers are developing and testing new ways to measure whether a treatment is working, including a symptom-based activity index and a score that predicts long-term s…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Antibiotics alone or surgery? study tracks which endocarditis patients fare better
Knowledge-focused OngoingInfective endocarditis is an infection of the heart's inner lining or valves. About half of patients need surgery during their hospital stay, while others receive antibiotics alone. Researchers are following 1,046 adults with confirmed endocarditis for up to 24 months to compare …
Sponsor: Centro Cardiologico Monzino • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can a new questionnaire capture life with hereditary amyloidosis?
Knowledge-focused CancelledResearchers in Argentina are developing and testing a self-administered questionnaire to measure how hereditary transthyretin amyloidosis affects patients' physical, emotional, and social quality of life. The study includes input from neurologists, a cardiologist, a psychologist,…
Sponsor: Hospital General de Niños Pedro de Elizalde • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
MD anderson study seeks to improve care for asian cancer patients
Knowledge-focused OngoingThis study aims to understand what helps or hinders a positive experience for Asian patients being treated for cancer at MD Anderson. Researchers will survey former patients and healthcare providers to identify key factors. The goal is to use these insights to improve care and su…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can a chatbot and teen mentors improve sexual health in Kenya's slums?
Knowledge-focused OngoingThis study tests a mobile chatbot called AskDoki, which provides age-appropriate sexual health information via WhatsApp, along with trained youth peer leaders (Digital Champions) who help teens access and use the program. About 610 adolescents aged 15-19 living in urban informal …
Sponsor: Pacific Institute for Research and Evaluation • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
Knowledge-focused OngoingThis study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Personalized risk reports may boost lung cancer screening and smoking cessation
Knowledge-focused By invitation onlyThis study tests whether giving smokers and former smokers a personalized risk report (based on clinical and genetic factors) helps doctors order lung cancer screening and helps patients follow through. About 915 participants will be randomly assigned to usual care or one of two …
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Tailored diet plans for Moms-to-Be: study pulled before start
Knowledge-focused CancelledThis study was designed to see if giving pregnant women nutrition advice based on their unique biology, lifestyle, and health could improve their health and their baby's health. It planned to enroll women less than 20 weeks pregnant, excluding those with high-risk conditions. How…
Sponsor: Jefferson Drapkin • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Real-World melanoma care under the microscope
Knowledge-focused OngoingResearchers are studying how advanced and metastatic melanoma is diagnosed and treated in everyday Spanish clinics. The study follows about 400 adults with stage III, metastatic, or unresectable melanoma from their first diagnosis. No experimental treatment is given; instead, the…
Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Blood and body fluid tests may reveal sepsis risk groups
Knowledge-focused By invitation onlyThis study is measuring certain substances in the blood, stool, saliva, and airway fluid of 200 adults with sepsis. The goal is to see if these biomarkers, combined with standard medical data, can predict which patients are more likely to die or develop long-term critical illness…
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Robotic surgery showdown: single port vs. multi port for prostate cancer
Knowledge-focused OngoingThis study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could a frailty score predict which older cancer patients survive intensive care?
Knowledge-focused OngoingOlder adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Healthy volunteers test new pill for obesity and diabetes – but only to see how food changes its effects
Knowledge-focused OngoingThis early-stage study looks at how taking a new tablet called CX11 with or without food changes the amount of drug in the blood. It involves 32 healthy adults and does not aim to treat any disease. The results will help researchers decide how to give the drug in future studies f…
Phase 1 • Sponsor: Vincentage Pharma Co., Ltd • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists dig into tissue samples to unravel lung scarring mystery
Knowledge-focused OngoingThis study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future the…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Smartwatch study aims to track cancer fatigue
Knowledge-focused OngoingThis pilot study is testing whether wearable activity trackers, like fitness watches, can help monitor fatigue in people with pancreatic or breast cancer who are undergoing treatment. Researchers want to see if patients will use the device daily and find it easy to use. The study…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can skin strength predict implant success? new study investigates
Knowledge-focused OngoingThis study looks at skin and soft tissue removed during breast implant surgery after mastectomy. Researchers want to see if the physical properties of the tissue can help predict complications like implant loss. The goal is to better understand risks and improve surgical outcomes…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive NCI study tracks thousands of cancer patients receiving standard care
Knowledge-focused By invitation onlyThis study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive farm study tracks Pesticide-Cancer links for decades
Knowledge-focused OngoingThis study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Real-World data sought on prostate cancer combo therapy
Knowledge-focused OngoingThis study watches how men with a certain advanced prostate cancer (mCRPC) do when taking the drugs olaparib and abiraterone in everyday medical practice. It will track about 250 patients for up to 2 years to see how long they stay on treatment and what happens next. The goal is …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
COVID-19 survivors tracked for 3 years to uncover hidden health impacts
Knowledge-focused OngoingThis study follows 583 adults who recovered from COVID-19 or were close contacts. Researchers will track their health, mental well-being, and immune responses over 3 years to understand long-term effects and whether prior infection prevents reinfection. Participants undergo regul…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Why COVID-19 hits blood cancer patients harder: scientists map the immune clues
Knowledge-focused OngoingResearchers at Peking University First Hospital are studying how the immune system responds to SARS-CoV-2 infection in people who have blood cancers compared with people who have no underlying diseases. The observational study enrolls 60 participants and collects clinical details…
Sponsor: Peking University First Hospital • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can mango and probiotics tame obesity inflammation? new study investigates
Knowledge-focused OngoingThis study looks at how compounds from mango (gallotannins) and a probiotic called Lactiplantibacillus pentosus affect gut bacteria and inflammation in people with obesity. Researchers will analyze stool samples from 20 participants (lean and obese) after giving them mango juice,…
Sponsor: Prairie View A&M University • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Could an algorithm replace the eye chart? a trial puts software-guided refraction to the test.
Knowledge-focused OngoingThis study tests whether a software program called the Vision Trainer can guide eyeglass prescriptions as accurately as the traditional manual method performed by trained examiners. Adults with myopia (nearsightedness) will have their prescriptions determined both ways, and the r…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Late-Night snacks and booze: a recipe for colon cancer?
Knowledge-focused OngoingThis study looks at how Western habits—like drinking alcohol and eating late—might raise the risk of colorectal cancer. Twelve adults who have had colon polyps in the past will try four different weekly routines, including eating at normal times or late, with or without alcohol. …
Sponsor: Rush University Medical Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches major study to unravel mysteries of rare genetic diseases
Knowledge-focused By invitation onlyThis study aims to identify genetic, biochemical, and clinical factors linked to disease severity in people with Gaucher disease and other lysosomal storage disorders. Researchers will evaluate up to 1,000 participants, including patients, carriers, and healthy controls, to bette…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Gene therapy patients monitored for 15 years to spot hidden side effects
Knowledge-focused By invitation onlyThis study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for diabetes genes in large study
Knowledge-focused PausedThis study looks at the genetic and molecular factors behind type 2 diabetes, obesity, and related complications like kidney disease. Researchers will collect health information, blood and urine samples, and perform tests like eye exams and ultrasounds from over 2,300 adults, foc…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a phone app help childhood cancer survivors keep track of their health?
Knowledge-focused OngoingResearchers at the University of California, San Francisco are testing a mobile app built for survivors of childhood cancer and their caregivers. The app shows each person their treatment history and follow-up recommendations, and sends messages to help them learn about their dia…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists watch HIV hideouts during suppression therapy
Knowledge-focused By invitation onlyThis study looks at HIV-infected adults who have been on antiretroviral therapy for a long time and have very low virus levels. Researchers want to see if the virus stays stable or changes over time. Participants visit the clinic every six months for blood tests and a special whi…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New catheter aims to sharpen liver cancer radiation targeting
Knowledge-focused OngoingThis study tests whether a special catheter (TriNav) helps deliver radiation more accurately to liver tumors. About 19 adults with liver cancer that cannot be removed by surgery will receive a test dose followed by the actual treatment. The goal is to see if the two doses match b…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Eye disease progression under the microscope: 3-Year study launched
Knowledge-focused OngoingThis study follows 400 people with intermediate age-related macular degeneration (AMD) for about 3 years. Researchers watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disease. No…
Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive cancer screening trial aims to cut deaths
Knowledge-focused OngoingThis study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
AI-Powered scans could speed up lung cancer radiation treatment
Knowledge-focused OngoingThis study looks at whether new AI tools can make adaptive radiotherapy—adjusting radiation plans during treatment—faster and easier for people with advanced lung cancer. Researchers will measure how long each step takes and compare plan quality using standard CT scans versus dai…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to boost genetic testing in cancer families
Knowledge-focused OngoingThis study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Tiny study probes Mitapivat's inner workings in sickle cell
Knowledge-focused OngoingThis observational study will examine how the drug mitapivat changes red blood cells in 6 people with sickle cell disease. Researchers will measure oxygen binding and cell survival markers from blood samples and muscle oxygen tests. The goal is to understand the drug's effects, n…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind family blood cancer clusters
Knowledge-focused OngoingThis long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can doctors safely watch small thyroid cancers instead of removing them?
Knowledge-focused OngoingResearchers at the University of Aarhus are studying whether people with a single thyroid cancer smaller than 2 cm can safely delay surgery and instead have the tumor monitored with ultrasound for five years. The study enrolls 90 adults aged 30 and older whose biopsy shows cancer…
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track flu antibodies for years to build better vaccines
Knowledge-focused By invitation onlyThis study follows 200 people who have had the flu to see how their immune system changes over two years. Participants give blood and nasal samples every three months. The goal is to learn how long antibodies last and how they change, which could help create more effective flu va…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Researchers hunt for muscle clues in rare dystrophy
Knowledge-focused OngoingThis pilot study looks at biomarkers in the blood of people with fragile sarcolemmal muscular dystrophy, a condition that makes muscle membranes weak. Researchers will collect blood samples at rest and after exercise during four 5-day hospital stays. The goal is to better underst…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
When cancer blocks the airway, doctors lack a playbook. experts aim to write one.
Knowledge-focused By invitation onlyTumours in the head, neck, or chest can narrow or distort the airway, and standard difficult-airway guidelines offer little cancer-specific advice. This study asks an international panel of anaesthesiologists, intensive care doctors, lung specialists, head and neck surgeons, and …
Sponsor: Onco Critical Care Society • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study aims to predict cancer return in Low-Risk patients
Knowledge-focused OngoingThis study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifyi…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Which Mini-Implant size works best? new study aims to find out
Knowledge-focused OngoingThis study tests two different diameters (1.6mm and 2mm) of mini-implants placed in the upper jaw to support orthodontic tooth movement. Twenty people receiving braces will get one size on each side of their mouth. Researchers will measure how stable the implants are, how much pa…
Sponsor: University of Baghdad • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Tongue-Tie surgery in infancy: do feeding, speech, and sleep problems return later?
Knowledge-focused By invitation onlyResearchers at the University of Alberta are following 500 children who had a tongue-tie release as infants to see how often they later develop feeding, speech, dental, or sleep and breathing problems that need further evaluation. Tongue tie is a shortened band under the tongue t…
Sponsor: University of Alberta • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track families to uncover Cancer's hidden causes
Knowledge-focused OngoingThis study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare bone cancer study hunts for hidden genetic triggers
Knowledge-focused OngoingThis study aims to find genetic changes that may cause sporadic chordoma, a rare bone cancer. Researchers will collect saliva and medical records from 188 patients across the U.S. and Canada who are the only ones in their family with chordoma. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can shedding pounds reshape the legs? a study tracks joint alignment after Weight-Loss surgery
Knowledge-focused OngoingThis observational study follows adults with morbid obesity who undergo bariatric surgery to see if substantial weight loss changes the alignment of their hips, knees, and ankles. Researchers measure leg alignment using standing X-rays before surgery and at 3, 6, and 12 months af…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a genetic test and MRI team up to improve prostate cancer treatment choices?
Knowledge-focused OngoingThis study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused By invitation onlyThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can shedding weight reshape the spine? a study tracks the changes
Knowledge-focused OngoingThis observational study follows adults with morbid obesity who undergo bariatric surgery to see how substantial weight loss affects the alignment of the spine and pelvis. Researchers measure spinal and pelvic positions on X-rays before surgery and again at 3, 6, and 12 months af…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New scan may predict chemo success in breast cancer patients
Knowledge-focused OngoingThis study looks at whether a special type of breast scan, called molecular breast imaging, can help doctors predict how well chemotherapy is working in women with invasive breast cancer. About 96 women will get the scan before, during, and after treatment. The goal is to see if …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC